header logo image


Page 5«..4567..10..»

Archive for the ‘Legal Issues Genetic Medicine’ Category

Robert Youngjohns, Chairman of the Board, ABBYY – Interview Series – Unite.AI

Thursday, May 14th, 2020

Jason Kingdon has been commercializing AI for over 25 years. He has a PhD from UCL Computer Science, he co-founded UCLs Intelligent Systems Lab in 1992 and pioneered one of the worlds first neural nets for live financial forecasting.

Jason is the Chairman and CEO of Blue Prism, a company that is unleashing the collaborative potential of humans and digital workers to transform the future of work, so every enterprise can exceed their business goals and drive growth with unmatched agility and speed.

Youve been involved in some form of AI for over 25 years now. What was it that attracted you to the space initially?

I became attracted to the artificial intelligence space because around the time I was in school earning my Ph.D. in intelligent systems and starting my career in research, there was a big boom in technology surrounding software with companies like Microsoft and Apple and Oracle. These organizations were using machines to solve problems people were facing on a daily basis and it was really enticing to become a part of this movement.

In 1992 you co-founded UCLs Intelligent Systems Lab. What were some of the projects that you worked on?

After co-founding UCLs Intelligent System Lab, I became founder/CEO of Searchspace, a successful UCL spinout project. We created Intelligent Transaction Monitoring Systems, which to this day are the global standard for money laundering and terrorist finance detection within the top-tier banks.

You were also responsible for introducing intelligent transaction monitoring on various exchanges such as the London Stock Exchange, and the New York Stock Exchange. Could you discuss the type of data that was being monitored and the type of AI implementation this was?

While we started Searchspace with broad ambitions for transaction monitoring, the project came to focus primarily on anti-money-laundering (AML) technology for banks and the middleware to link it to other systems. We produced an intelligent system that worked for the London Stock Exchange, the New York Stock Exchange, and others.

You also formed a private AI research lab called glass.ai. What was the mission of glass.ai?

The mission of glass.ai was and is to read and interpret vast quantities of textual data whether from websites, news, proprietary databases or other sources at scale, using AI to combine semantic analysis and resource crawling.

You then joinedBlue Prism as Executive Chairman, could you discuss what attracted you to this company?

I was drawn to Blue Prism in 2007 because of the ingenious way that theyd solved the operational inefficiencies within the banking sector where human workers perform repetitive tasks by interoperating between enterprise-wide IT systems. Traditional IT methods couldnt easily address this, as they were focusing on big ticket items, so a more agile automation solution was created by Blue Prism that could be run by non-technical business people but in a highly secure and regulated way.

What really impressed me was how theyd advanced business automation in such an elegant, light way taking the user interface seriously and repurposing it as a machine interface. Focusing on the interface meant that you can theoretically connect it to any past present or future system. The significance of this breakthrough was very clear to me especially when at Searchspace, clients always wanted extra things that involved integration with other systems.

Blue Prism solved these system interoperability challenges by pioneering robotic process automation (RPA) software that runs a pre-built, Digital Worker a software robot that automates tasks over any third-party system independently of machine APIs. Another breakthrough was that the Digital Worker uniquely used AI techniques to carry out tasks in the same way humans do but much faster and more accurately. I also saw RPA as a potential route for organizations being able to more easily test and then deploy any new transformative tech innovation.

The real light bulb moment came when I was introduced to a major UK online retailer who was an early Blue Prism RPA adopter. I was introduced to Kate an employee who ran the robots, and shed recently used them to reverse overpayments on 2,000 accounts. What amazed me was this complex activity was performed in less than 1 day, but without that robotic capability, the same activity would have taken a number of staff over three weeks to complete.

I believed that commercializing AI-powered automation in this way would have a profound effect on business and society. Blue Prism really understood and embraced this from the beginning and thats been reflected in the companys efforts every step of the way.

What has your journey with Blue Prism been like so far?

So far, it has been very exciting, fast-paced, challenging, all-encompassing and rewarding. Since investing in the business in 2007, Ive spent my time as Chairman driving our growth and vision strategy, and helping take the company public in 2016. This IPO provided the engine for growth and product development while providing the means for us to make critical investments, such as the acquisition of Thoughtonomy in 2019.

Im proud to say that over the last four years, weve gone from 60 to over 1,000 people, were selling in 170 countries to 70 commercial sectors and are approaching 1700 customers including many of the worlds biggest brands.

In fact, we recently reported achievingthe fastest revenue growthof all large UK public software companies for the fourth consecutive year in 2019.

As Chairman and CEO, Im now shaping and evolving our product roadmap that takes RPAinto the AI era while working tirelessly to promote the vision of a Digital Workforce for every enterprise. In my vision for the future, businesses will have a new organizational structure one-third human employees, one-third Digital Workers, and one-third core IT. Human workers will continue to provide strategy and creative thinking, Digital Workers will execute on business processes, and core IT will provide the underlying technology infrastructure and data storage.

With Thoughtonomy, in addition to its cloud capabilities, the acquisition is providing access to analytics that enable better ways of looking at the Digital Workers, seeing how they are deployed, seeing all the activities taking place. We are also working on ways to enhance the way Digital Workers and humans interact. The interplay between humans and Digital Workers is absolutely part and parcel of the enterprise vision and a Digital Workforce in every organization.

In the new operating environment recently created by COVID-19, our Digital Workers are arguably more important than ever in driving organizational adaptation and resilience. We are working to meet this demand by helping organizations to maintain business continuity and resilience to alleviate operational challenges through intelligent automation.

Blue Prism helps companies deliver robotic process automation (RPA) with a step-by-step methodology for a smooth implementation. For people not familiar with RPA, could you discuss what it is and how it can benefit different enterprises?

Our RPA technology runs an AI-powered, Digital Workforce; a self-organizing, multi-tasking, intelligent, processing resource thats trained and run by business to safely automate evermore complex, end-to-end, business activities faster and more accurately than humans. This enables our customers to exceed their business goals and drive meaningful growth, resilience and continuity with unmatched speed and agility.

To deliver results fast, Digital Workers arrive already pre-built and can simply be trained by business people without coding skills and put to work using a centralized operating system to draw, create and publish process automations. Digital Workers amplify gains by compounding how work is carried out as published automations and all related innovations are centralized to be shared, reused and improved by the whole business.

Digital Workers are managed by humans with our industry-leading, Robotic Operating Model delivery methodology that provides the most effective, proven way to; business-align, organize, identify, design, test, deploy and sustain process automations at scale so business-led, IT approved, enterprise-wide transformation is achieved. All Digital Workers are easy to deploy, manage, upgrade, scale and can be used by remote-working employees due to an availability on-premises, in the cloud, hybrid, or as an integrated SaaS solution.

We are helping organizations operating in all sectors achieve 6 areas of proven value delivery:

Could you discuss why you believe the Blue Prism solution is superior to competing RPA product offerings?

Our Digital Workers achieve greater transformational potential across the enterprise than other competitor robots as they possess business-led, no-code, centralized, design principles.

Our Digital Workers are also equipped with what we believe are the following totally unique attributes:

Competitive RPA offerings favor a form of digital assistant for a single person to perform all kinds of time-saving activity. And thats great, but its not taking full advantage of RPA in an enterprise environment. This is because robots that are distributed across individuals desktops and used in individual, soiled, contexts may help the individual but wont enable any benefits to be scaled and experienced by the whole enterprise.

Another major consideration is that due to a growing scarcity of software development skills, those robots that require any coding will ultimately suffer the same high costs and deployment delays as traditional IT projects.

What is the Blue Prism Digital Exchange (DX)?

The Blue Prism Digital Exchange (DX) is a ground-breaking intelligent automation app store and online community that offers an open ecosystem for intelligent automation capabilities. The Blue Prism DX offers connections to all transformative technologies which are simply dragged and dropped into process flows to be used for the continual testing, advancing, sharing and deployment of new automated innovations. This could be new AI, machine learning, chatbot and other cognitive capabilities. Blue Prisms DX is significant as its now driving those AI capabilities into the wider enterprise which is something that organizations would previously never have been able to experience.

Thank you for the interview. Anyone who wishes to learn more should visit Blue Prism.

Original post:
Robert Youngjohns, Chairman of the Board, ABBYY - Interview Series - Unite.AI

Read More...

Michelle Cretella is Back – Along With Her Sophistry – The Slowly Boiled Frog

Saturday, April 25th, 2020

If Dr. Michelle Cretella disagrees with the science then she should publish. She never has and she never will because she can't.

The pediatrician that Murphee is referring to is Michelle Cretella, executive director of American College of Pediatricians (ACPeds). Southern Poverty Law Center deems ACPeds to be an anti-LGBTQ hate group as well.

Before we wander into the text it is important to understand that Michelle Cretella's point of view is not as a physician. Not at all. Cretella is a Catholic extremist. Cretella conforms to Vatican doctrine, no matter how idiotic that might be and, according to the Vatican, transgender people do not really exist.

As for Murphee's title, insanity is substituting religious dogma for medical science. The dogma emanates from celibate prelates who are theologians and catechists with no training or experience in medical science.

And we begin

Junk scientist! they shout. Hater!

All lies.

She is, however, a formidable foe of the transgender activist agenda and in its view, a villain to be destroyed.

Furthermore, Michelle Cretella is not a foe of mythical activists. Rather, Cretella is a foe of gender-affirming care which is the clinical standard of care according to her former peer group, the American Academy of Pediatrics.

Michelle Cretella is in a battle of her own making. The two sides are religious dogma vs. medical science. But it is not that simple. Cretella is intellectually dishonest. She is promoting faith-based Catholic doctrine as if it were evidence-based science. That constitutes the big lie.

Speaking of bullshit

I have no quarrel with what Mr. Murphee calls biblical truths other than the fact that scripture might have been accepted as truth when it was written but is not scientifically truthful today. Even then, Cretella's religious beliefs are hers to hold. Yet, she is not entitled to promote religious beliefs as science.

Cretella is claiming, essentially, that a sinister conspiracy to intentionally damage children exists. Doctors and educators and the media and secular people and They are allin on it.

If she believes that she has a better treatment plan for acute pediatric gender dysphoria then she should do what experts in this area routinely do which is to publish findings to reputable academic journals. She never has. She cannot.

As for surgery (which Murphee presents for shock value), about 30% of transgender people have gender-affirming surgery. At least a year of behavioral health therapy is required for a patient to qualify. Is 30% many?

No transgender person gives a flying fuck whether or not Murphee or Cretella approve of them. Transgender people are entitled to common courtesy. In polite society, we address people as they choose to be addressed. Trans people expect to be addressed according to their gender.

Misgendering trans people particularly trans kids does violence to them. It is gratuitously cruel to misgender trans people as a means of demonstrating disapproval. Doing so is a form of arrogance.

Misgendering is a false message that an individual's approval has been solicited (it has not). Then that individual feels compelled to demonstrate that their approval is withheld. It is entirely unnecessary.

Murphee and Cretella believe two things about me (and then some): They believe that, because I am gay, I am objectively disordered. Because I am Jewish they believe that I am destined to go to Hell.

I really do not care what they believe. If they call me a faggot kike that gets my attention. Belief and conduct are two different things.Is expecting people to be polite really so burdensome?

Referring to the construct of gender as separate from natal sex:

Again, if Cretella disagrees with the science then she should publish. Comments at one of AFA's outlets is not the equivalent of publishing to a reputable academic journal.

Cretella has never published because her views are based on religion in contrast to science. She is also a demagogue. No one is attacking children and children are not candidates for surgery. Furthermore, Cretella seeks to substitute her religious judgment for that of clinicians and parents.

Let us review what Cretella calls an attack. Prepubescent children transition if a) they are in distress and; b) if transitioning offers relief. Transitioning means gender-conforming clothes and hair. No drugs whatsoever.After entering puberty (Tanner stage 2 or 3) adolescents might be provided with puberty blockers which are fully reversible according to the Endocrine Society.

According to the Mayo Clinic, for children who have gender dysphoria, suppressing puberty might:

If an adolescent child stops taking GnRH analogues, puberty will resume.

The administration of hormones is not gratuitous chemistry. It requires a clinical evaluation, a mental health evaluation, informed consent and parental consent. Consent means a demonstrable understanding of risks and benefits.

A simple and simplistic comment triggers a verbose rebuttal but we all need to separate science from religious ideology.

Off into a land where reality is optional

Thats simply insane! Cretella exclaimed. Its contrary to reality and to a Judeo-Christian worldview. Sex is determined. Its not assigned. Its determined at fertilization. If you have a Y chromosome, you will go down the male pathway. If youre missing the Y chromosome, youll go down the female pathway.

Cretella is being dishonest. She knows perfectly well that sex assigned at birth is a means of communicating the difference between natal sex from gender. It is applicable to a very small percentage of the population.

A feeble attempt to claim that science is on their side

As adults, physical differences between men and women account for many of their contrasting thought patterns and behaviors, even if they agree in principle on important areas of life, e.g., parenting.

This all goes on for several paragraphs. Cretella uses the opportunity to take a dishonest swipe at marriage equality (which I will ignore) and there is this:

The worst side effects of puberty blocking may include brittle bones, obesity, testicular cancer, memory problems, and [if combined with cross-sex hormones] permanent sterilization, Cretella reported. This is child abuse.

Parents and the adolescent provide informed consent. They are aware of the potential side effects but make a considered judgment that the benefits outweigh the risks. Cretella has no experience in this area. Cretella has minimal training in endocrinology.

Notice how Cretella doesn't establish what that real help is. Children have rights too including the right to be treated according to the best available medical science.

Look! It's a bullshit kabob. Yum!

At long last the witch and her fluffer identify this as a religious issue

To declare that our bodies dont matter, she added, is diametrically opposed to Christian theology. The Incarnate Word. God how did He save? He saved us by taking on a human body. This is significant.

To believe our body is just this container, and it doesnt matter thats in line with reincarnation, Hinduism, Buddhism! It is the age-old conflict between a pagan worldview and a Christian one.

Related content:

Go here to read the rest:
Michelle Cretella is Back - Along With Her Sophistry - The Slowly Boiled Frog

Read More...

Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race – Raw Story

Saturday, April 25th, 2020

There is no scientific evidencethat the novel coronavirus was bioengineered, but its origins are not entirely clear. Deadly pathogens discovered in the wild can be studied in secret in biowarfare labs and sometimes made more dangerous. That possibility, and other plausible scenarios, have been incorrectly dismissed in remarks by some scientists andgovernment officials, and in the coverage of most major media outlets.

Regardless of the source of this pandemic, there is considerable documentation that a global biological arms race going on outside of public view could produce even more deadly pandemics in the future.

While much of the media and political establishment have minimized the threat from such lab work, some hawks on the American right like Sen. Tom Cotton, R-Ark., have singled outChinese biodefense researchers as uniquely dangerous.

But there is every indication that U.S. lab work is every bit as threatening as that in Chinese labs. American labs also operate insecret, and are also known to beaccident-prone.

The current dynamics of the biological arms race have been driven by U.S. government decisions that extend back decades. In December 2009, Reuters reported that the Obama administration was refusing even to negotiate the possible monitoring of biological weapons.

Much of the left in the U.S. now appears unwilling to scrutinize the origin of the pandemic or the wider issue of biowarfare perhaps because portions of the anti-Chinese right have been sovocal in making unfoundedallegations.

Governments that participate in such biological weapon research generally distinguish between biowarfare and biodefense, as if to paint such defense programs as necessary. But this is rhetorical sleight-of-hand; the two concepts are largely indistinguishable.

Biodefense implies tacit biowarfare, breeding more dangerous pathogens for the alleged purposeof finding a way tofightthem. While this work appears to have succeeded in creating deadly and infectious agents, including deadlier flu strains, such defense research is impotent in its ability to defend us from this pandemic.

The legal scholar who drafted the main U.S. law on the subject, Francis Boyle, warned in his 2005 book Biowarfare and Terrorism that an illegal biological arms race with potentially catastrophic consequences was underway, largely driven by the U.S. government.

For years,many scientistshave raised concerns regarding bioweapons/biodefense lab work, and specifically aboutthe fact that huge increases in funding have taken place since 9/11. This was especially true afterthe anthrax-by-mail attacks that killed five people in the weeks after 9/11, which the FBI ultimately blamed on a U.S. government biodefense scientist.A 2013 study found that biodefense funding since2001 hadtotaled at least $78 billion, and more has surely been spent since then. This has led to aproliferation of laboratories, scientists and new organisms, effectively setting off a biological arms race.

Following the Ebola outbreak in west Africa in 2014, the U.S. governmentpaused fundingfor what are known as gain-of-function research on certain organisms. This work actually seeks to make deadly pathogensdeadlier, in some cases making pathogens airborne thatpreviously were not. With little notice outside the field, the pause on such research was lifted in late 2017.

During this pause, exceptions for funding were made for dangerous gain-of-function lab work. This included work jointly done by U.S. scientists from the University of North Carolina, Harvard and the Wuhan Institute of Virology. This work which had funding from USAID and EcoHealth Alliance not originally acknowledged was published in2015 in Nature Medicine.

A different Nature Medicine article about the origin of the current pandemic,authored by five scientists andpublished on March 17,has been touted by major media outlet and some officials including current National Institutes of Health directorFrancis Collins as definitively disproving a lab origin for the novel coronavirus. That journal article, titled The proximal origin of SARS-CoV-2, stated unequivocally: Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus. This is a subtly misleading sentence. While the scientists state that there is no known laboratory signature in the SARS-Cov-2 RNA, their argument fails to take account of other lab methods that could have created coronavirus mutations without leaving such a signature.

Indeed, there is also thequestion of conflict of interest in the Nature Medicine article. Some of the authors of that article, as well as aFebruary 2020Lancet letter condemning conspiracy theories suggesting that COVID-19 does not have a natural origin which seemed calculated to minimize outside scrutiny of biodefense lab work have troubling ties to thebiodefense complex,as well as to the U.S. government. Notably, neither of these articles makes clear that a virus can have a natural originand then be captured and studied in a controlled laboratory setting before being let loose, either intentionally or accidentallywhichis clearly a possibility in the case of the coronavirus.

Facts as rumors

This reporter raised questions about the subject at a news conference with a Center for Disease Control (CDC) representative at the now-shuttered National Press Club on Feb. 11. I asked if it was a complete coincidence that the pandemic had started in Wuhan, the only place in China with a declared biosafety level 4 (BSL4) laboratory. BSL4 laboratories have the most stringent safety mechanisms, but handle the most deadly pathogens. As I mentioned, it was oddthat the ostensible origin of the novel coronavirus was bat caves in Yunnan province more than 1,000 miles from Wuhan. I noted that gain-of-function lab work can results in more deadly pathogens, and that major labs, including some in the U.S., have had accidental releases.

CDC Principal Deputy Director Anne Schuchat saidthatbased on the information she had seen, the virus was of zoonotic origin. She also stated, regarding gain-of-function lab work, that it is important to protect researchers and their laboratory workers as well as the community around them and that we use science for the benefit of people.

I followed up by asking whether an alleged natural origin did not preclude the possibility that this virus came through a lab, since a lab could have acquired a bat virus and been working on it. Schuchat replied to the assembled journalists that it is very common for rumors to emerge that can take on life of their own, but did not directly answer the question. She noted that in the 2014 Ebola outbreak some observers had pointed to nearby labs as the possible cause, claiming this was a key rumor that had to be overcome in order to help control the outbreak. She reiterated: So based on everything that I know right now, I can tell you the circumstances of the origin really look like animals-to-human. But your question, I heard.

This is no rumor. Its a fact: Labs work with dangerous pathogens. The U.S. and China each have dual-use biowarfare/biodefense programs. China has major facilities at Wuhan a biosafety level 4 lab and a biosafety level 2 lab. There are leaks from labs. (See Preventing a Biological Arms Race, MIT Press, 1990, edited by Susan Wright; also, a partial review in Journal of International Law from October 1992.)

Much of the discussion of this deadly serious subject is marred with snark that avoids or dodges the gain-of-function question. ABC ran a story on March 27 titled Sorry, Conspiracy Theorists. Study Concludes COVID-19 Is Not a Laboratory Construct.' That story did not address the possibility that the virus could have been found in the wild, studied in a lab and thenreleased.

On March 21, USA Today published a piece headlined Fact Check: Did the Coronavirus Originate In a Chinese Laboratory? and rated it FALSE.

That USA Today story relied ona widely cited Feb.17 piece inthe Washington Post, titled Tom Cotton keeps repeating a coronavirus conspiracy theory that was already debunked. That article quoted public comments fromRutgers University professor of chemical biology Richard Ebright, but out of context and only in part. Specifically, the story quoted from Ebrights tweet that the coronavirus was not an engineered bioweapon. In fact, his full quote included the clarification that the virus could have entered human population through lab accident. (An email requesting clarification sent toPost reporterPaulina Firoziwas met with silence.)

Bioengineered From a lab

Other pieces in the Post since then (some heavily sourced to U.S. government officials) have conveyed Ebrights thinking, but it gets worse. In a private exchange, Ebright who, again, has said clearly that the novel coronavirus was not technically bioengineered using known coronavirus sequences stated that other forms of lab manipulation could have beenresponsible for the current pandemic. This runs counter to much reporting, which is perhaps too scientifically illiterate to perceive the difference.

In response to the suggestion that the novel coronavirus could have come about through various methodsbesides bioengineering made by Dr. Meryl Nass, who has done groundbreaking work on biowarfareEbright responded in an email:

The genome sequence of SARS-CoV-2 has no signatures of human manipulation.

This rules out the kinds of gain-of-function (GoF) research that leave signatures of human manipulation in genome sequences (e.g., use of recombinant DNA methods to construct chimeric viruses), but does not rule out kinds of GoF research that do not leave signatures (e.g., serial passage in animals). [emphasis added]

Very easy to imagine the equivalent of the Fouchiers 10 passages in ferrets with H5N1 influenza virus, but, in this case, with 10 passages in non-human primates with bat coronavirus RaTG13 or bat coronavirus KP876546.

That last paragraph is very important. It refersto virologist Ron Fouchier of the Erasmus Medical Center in Rotterdam, who performed research on intentionally increasing rates of viralmutation rate by spreading a virus from one animal to another in a sequence.The New York Times wrote about this in an editorial in January 2012, warning of An Engineered Doomsday.

Now scientists financed by the National Institutes of Health have created a virus that could kill tens or hundreds of millions of people if it escaped confinement, the Times wrote. The story continued:

Working with ferrets, the animal that is most like humans in responding to influenza, the researchers found that a mere five genetic mutations allowed the virus to spread through the air from one ferret to another while maintaining its lethality. A separate study at the University of Wisconsin, about which little is known publicly, produced a virus that is thought to be less virulent.

The word engineering in the New York Times headline is technically incorrect, sincepassing a virus through animals is not genetic engineering. This same distinction has hindered some from understanding the possible origins of the current pandemic.

Fouchiers flu work, in which an H5N1 virus was made more virulent by transmitting it repeatedly between individual ferrets, briefly sent shockwaves through the media. Locked up in the bowels of the medical faculty building here and accessible to only a handful of scientists lies a man-made flu virus that could change world history if it were ever set free, wrote Science magazine in 2011 in a story titled Scientists Brace for Media Storm Around Controversial Flu Studies. It continues:

The virus is an H5N1 avian influenza strain that has been genetically altered and is now easily transmissible between ferrets, the animals that most closely mimic the human response to flu. Scientists believe its likely that the pathogen, if it emerged in nature or were released, would trigger an influenza pandemic, quite possibly with many millions of deaths.

In a 17th floor office in the same building, virologist Ron Fouchier of Erasmus Medical Center calmly explains why his team created what he says is probably one of the most dangerous viruses you can make and why he wants to publish a paper describing how they did it. Fouchier is also bracing for a media storm. After he talked to ScienceInsider yesterday, he had an appointment with an institutional press officer to chart a communication strategy.

Fouchiers paper is one of two studies that have triggered an intense debate about the limits of scientific freedom and that could portend changes in the way U.S. researchers handle so-called dual-use research: studies that have a potential public health benefit but could also be useful for nefarious purposes like biowarfare or bioterrorism.

Despite objections, Fouchiers article was published by Science in June 2012. Titled Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets, it summarized how Fouchiers research team made the pathogen more virulent:

Highly pathogenic avian influenza A/H5N1 virus can cause morbidity and mortality in humans but thus far has not acquired the ability to be transmitted by aerosol or respiratory droplet (airborne transmission) between humans. To address the concern that the virus could acquire this ability under natural conditions, we genetically modified A/H5N1 virus by site-directed mutagenesis and subsequent serial passage in ferrets. The genetically modified A/H5N1 virus acquired mutations during passage in ferrets, ultimately becoming airborne transmissible in ferrets.

In other words, Fouchiers research took a flu virus that did not exhibit airborne transmission, then infected a number of ferrets until it mutated to the point that it was transmissible by air.

In thatsame year, 2012, asimilar studyby Yoshihiro Kawaoka of the University of Wisconsin was published in Nature:

Highly pathogenic avian H5N1 influenza A viruses occasionally infect humans, but currently do not transmit efficiently among humans. Here we assess the molecular changes that would allow a virus to be transmissible among mammals. We identified a virus with four mutations and the remaining seven gene segments from a 2009 pandemic H1N1 virus that was capable of droplet transmission in a ferret model.

In 2014, Marc Lipsitch of Harvard and Alison P. Galvani of Yale wrote regarding Fouchier and Kawaokas work:

Recent experiments that create novel, highly virulent and transmissible pathogens against which there is no human immunity are unethical they impose a risk of accidental and deliberate release that, if it led to extensive spread of the new agent, could cost many lives. While such a release is unlikely in a specific laboratory conducting research under strict biosafety procedures, even a low likelihood should be taken seriously, given the scale of destruction if such an unlikely event were to occur. Furthermore, the likelihood of risk is multiplied as the number of laboratories conducting such research increases around the globe.

Given this risk, ethical principles, such as those embodied in the Nuremberg Code, dictate that such experiments would be permissible only if they provide humanitarian benefits commensurate with the risk, and if these benefits cannot be achieved by less risky means.

We argue that the two main benefits claimed for these experiments improved vaccine design and improved interpretation of surveillance are unlikely to be achieved by the creation of potential pandemic pathogens (PPP), often termed gain-of-function (GOF) experiments.

There may be a widespread notion that there is scientific consensus that the pandemic did not come out of a lab. But in factmany of the most knowledgeable scientists in the field are notably silent. This includes Lipsitch at Harvard, Jonathan A. King at MITand many others.

Just last year, Lynn Klotz of the Center for Arms Control and Non-Proliferation wrote a paperin the Bulletin of the Atomic Scientistsentitled Human Error in High-biocontainment Labs: A Likely Pandemic Threat. Wrote Klotz:

Incidents causing potential exposures to pathogens occur frequently in the high security laboratories often known by their acronyms, BSL3 (Biosafety Level 3) and BSL4. Lab incidents that lead to undetected or unreported laboratory-acquired infections can lead to the release of a disease into the community outside the lab; lab workers with such infections will leave work carrying the pathogen with them. If the agent involved were a potential pandemic pathogen, such a community release could lead to a worldwide pandemic with many fatalities. Of greatest concern is a release of a lab-created, mammalian-airborne-transmissible, highly pathogenic avian influenza virus, such as the airborne-transmissible H5N1 viruses created in the laboratories of Ron Fouchier in the Netherlands and Yoshihiro Kawaoka in Madison, Wisconsin.

Crazy, dangerous

Boyle, a professor of international law at the University of Illinois, has condemned Fouchier, Kawaoka and others including at least one of the authors of the recent Nature Medicine article in the strongest terms, calling such work a criminal enterprise. While Boyle has been embroiled in numerous controversies, hes been especially dismissed by many on this issue. The fact-checking websiteSnopeshas described him as a lawyer with no formal training in virology without noting that he wrote the relevant U.S. law.

As Boyle saidin 2015:

Since September 11, 2001, we have spent around $100 billion on biological warfare. Effectively we now have an Offensive Biological Warfare Industry in this country that violates theBiological Weapons Conventionand myBiological Weapons Anti-Terrorism Act of 1989.

The law Boyle drafted states: Whoever knowingly develops, produces, stockpiles, transfers, acquires, retains, or possesses any biological agent, toxin, or delivery system for use as a weapon, or knowingly assists a foreign state or any organization to do so, shall be fined under this title or imprisoned for life or any term of years, or both. There is extraterritorial Federal jurisdiction over an offense under this section committed by or against a national of the United States.

Boyle also warned:

Russia and China have undoubtedly reached the same conclusions I have derived from the same open and public sources, and have responded in kind. So what the world now witnesses is an all-out offensive biological warfare arms race among the major military powers of the world: United States, Russia, Britain, France, China, Israel, inter alia.

We have reconstructed the Offensive Biological Warfare Industry that we had deployed in this county before its prohibition by the Biological Weapons Convention of 1972, described by Seymour Hersh in his groundbreaking expose Chemical and Biological Warfare: Americas Hidden Arsenal. (1968)

Boyle now states that he has been blackballed in the media on this issue, despite his having written the relevant statute. The group he worked with on the law, the Council for Responsible Genetics, went under several years ago, making Boyles views against biodefense even more marginal as government money for dual use work poured into the field and criticswithin the scientific community have fallen silent. In turn, his denunciationshave grown more sweeping.

In the 1990 book Preventing a Biological Arms Race, scholar Susan Wright argued that current laws regarding bioweapons were insufficient, as there were projects in which offensive and defensive aspects can be distinguished only by claimed motive. Boyle notes, correctly, that current law he drafted does not makean exception for defensive work, but only for prophylactic, protective or other peaceful purposes.

While Boyle is particularly vociferous in his condemnations, he is not alone. There has been irregular, but occasional media attention to this threat. The Guardian ran a piece in 2014,Scientists condemn crazy, dangerous creation of deadly airborne flu virus, afterKawaoka created a life-threatening virus that closely resembles the 1918 Spanish flu strain that killed an estimated 50m people:

The work they are doing is absolutely crazy. The whole thing is exceedingly dangerous, said Lord May, the former president of the Royal Society and one time chief science adviser to the UK government. Yes, there is a danger, but its not arising from the viruses out there in the animals, its arising from the labs of grossly ambitious people.

Boylescharges beginning early this yearthat the coronavirus was bioengineered allegationsrecently mirrored by French virologist andNobel laureate Luc Montagnier have not been corroborated by any publicly produced findings of any U.S. scientist. Boyle even charges that scientists like Ebright, who is at Rutgers, arecompromised because the university got abiosafety level 3 lab in 2017though Ebright is perhaps the most vocal eminent critic of this research, among U.S. scientists. These and other controversies aside, Boyles concerns about the dangers of biowarfare arelegitimate; indeed, Ebright shares them.

Some of the most vocal voices to discuss the origins of the novel coronavirushave been eager to minimizethe dangers of lab work, or have focused almost exclusively on wet markets or exotic animals as the likely cause.

The media celebrated Laurie Garrett, the Pulitzer Prizewinning author and former senior fellow at the Council on Foreign Relations, when she declared on Twitter on March 3 (in a since-deleted tweet)that the origin of the pandemic was discovered: Its pangolins. #COVID19 Researchers studied lung tissue from 12 of the scaled mammals that were illegally trafficked in Asia and found #SARSCoV2 in 3. The animals were found in Guangxi, China. Another virus+ smuggled sample found in Guangzhou.

She was swiftly corrected by Ebright: Arrant nonsense. Did you even read the paper? Reported pangolin coronavirus is not SARS-CoV-2 and is not even particularly close to SARS-CoV-2. Bat coronavirus RaTG13 is much closer to SARS-CoV-2 (96.2% identical) than reported pangolin coronavirus (92.4% identical). He added: No reason to invoke pangolin as intermediate. When A is much closer than B to C, in the absence of additional data, there is no rational basis to favor pathway A>B>C over pathway A>C. When someone asked what Garrett was saying, Ebright responded: She is saying she is scientifically illiterate.

The following day, Garrett corrected herself (without acknowledging Ebright): I blew it on the #Pangolins paper, & then took a few hours break from Twitter. It did NOT prove the species = source of #SARSCoV2. Theres a torrent of critique now, deservedly denouncing me & my posting. A lot of the critique is super-informative so leaving it all up 4 while.

At leastone Chinese governmentofficialhas respondedto the allegation that the labs in Wuhan could be the source for the pandemic by alleging that perhaps the U.S. isresponsibleinstead. In American mainstreammedia, that has been reflexivelytreated as evenmore ridiculousthan the original allegation that the virus could havecome froma lab.

Obviouslythe Chinese governmentsallegations should not be taken at face value, but neither should U.S. government claims especially considering that U.S. government labs were the apparent source for theanthrax attacks in 2001. Those attacks sent panic through the U.S. and shut down Congress, allowing the Bushadministration to enact the PATRIOT Act and ramp up the invasions of Afghanistan and Iraq. Indeed, in October2001, media darlings like Richard Butler and Andrew Sullivan propagandizedfor war with Iraq because of the anthrax attacks. (Although it turned out that neither Iraq nor al-Qaida was involved.)

The 2001 anthrax attacks also provided muchof the pretext forthe surge in biolab spending since then, even though they apparently originated in a U.S. or U.S.-allied lab. Indeed, thoseattacks remain shrouded in mystery.

The U.S. government has also come up withelaborate cover stories to distract from its bioweapons work. For instance, the U.S. government infamously claimed the 1953 death of Frank Olson, a scientist at Fort Detrick, Maryland, was anLSD experiment gone wrong;it now appears to have been an execution to cover up for U.S.biological warfare.

Regardless of the cause of the current pandemic, these biowarfare/biodefense labs need far more scrutiny. The call to shut them down by Boyle and others needs to be clearly heard and light must be shone on precisely what research is being conducted.

The secrecy of these labs may prevent us ever knowing with certainty the origins of the current pandemic. It could have been a lab release, presumably accidental, or it could have been a zoonotic, or animal-to-human, infection

What we do know is this lab work comes with real dangers. One might make a comparison to climate change: We cannot attribute an individual hurricane to man-made climate disruption,yet science tells us that human activity makes stronger hurricanes more likely. Thatbrings us back to the imperative to cease the kinds of activities thatproduce such dangers in the first place.

If that doesnt happen, the people of the planet will be at the mercy of the machinations and mistakes of state actors who are playing with fire for their geopolitical interests.

Sam Husseini is a writer and political activist. He is communications director of the Institute for Public Accuracy, a Washington-based nonprofit that promotes progressive experts as alternative sources for mainstream media reporters. He tweets @samhusseini.

then let us make a small request. The COVID crisis has cut advertising rates in half, and we need your help. Like you, we here at Raw Story believe in the power of progressive journalism. Raw Story readers power David Cay Johnstons DCReport, which we've expanded to keep watch in Washington. Weve exposed billionaire tax evasion and uncovered White House efforts to poison our water. Weve revealed financial scams that prey on veterans, and legal efforts to harm workers exploited by abusive bosses. And unlike other news outlets, weve decided to make our original content free. But we need your support to do what we do.

Raw Story is independent. Unhinged from corporate overlords, we fight to ensure no one is forgotten.

We need your support in this difficult time. Every reader contribution, whatever the amount, makes a tremendous difference. Invest with us. Make a one-time contribution to Raw Story Investigates, or click here to become a subscriber. Thank you. Click to donate by check.

then let us make a small request. The COVID crisis has cut advertising rates in half, and we need your help. Like you, we believe in the power of progressive journalism and were investing in investigative reporting as other publications give it the ax. Raw Story readers power David Cay Johnstons DCReport, which we've expanded to keep watch in Washington. Weve exposed billionaire tax evasion and uncovered White House efforts to poison our water. Weve revealed financial scams that prey on veterans, and efforts to harm workers exploited by abusive bosses. We need your support to do what we do.

Raw Story is independent. You wont find mainstream media bias here. Every reader contribution, whatever the amount, makes a tremendous difference. Invest with us in the future. Make a one-time contribution to Raw Story Investigates, or click here to become a subscriber. Thank you.

Read the rest here:
Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race - Raw Story

Read More...

I’m Sorry, What? – Outside The Beltway – Mobile Edition

Saturday, April 25th, 2020

Trump made some odd suggestions on today's Al Presidente.

Steven L. Taylor Thursday, April 23, 2020 82 comments

Bloomberg reports: Trump Sees Coronavirus Hope in Summer, Sunlight and Bleach

The virus is dying at a much more rapid pace from exposure to humidity or heat, Bill Bryan, an undersecretary at the Homeland Security Department, said at a White House news conference on Thursday.

[]

Bryan suggested the new U.S. research offered practical tips for many Americans, including increasing the temperature and humidity for potentially contaminated indoor spaces in order to kill the virus on surfaces. At a temperature of 70 to 75 degrees Fahrenheit and 80% humidity in the summer sun, for example, the research showed the virus would last just two minutes on a porous surface. Dry environments Bryan said, may require extra care.

Very Powerful Light

Trump appeared intrigued by the research after Bryans presentation.

Suppose we hit the body with a tremendous ultraviolet or just very powerful light, Trump said, following Bryans presentation. I think that hasnt been checked but youre going to test it.

Researchers could also bring the light inside the body Trump said, either through the skin or in some other way.

[]

Bryan also said that research had shown bleach could kill the virus in saliva or respiratory fluids in five minutes and isopropyl alcohol could kill it even more quickly. Trump suggested there would be more testing there, too.

The disinfectant knocks it out in a minute. One minute, he said. Is there a way we can do something like that by injection inside? He said it would be almost a cleaning. It gets in the lungs and does a tremendous number on the lungs.

(Emphases mine).

In case you cant believe what you just read:

I am not sure which is crazier, the notion that cleaner could be used or light could be put inside the body (although, really, does one have to rank in this case?).

Unlike the President of the United States, the Bloomberg report cautions:

Disinfecting surfaces is an important practice in infection control. The coronavirus is fragile outside the body, and is essentially a packet of genetic information wrapped in a packet of lipids. Hand washing with soap is particularly effective in cleaning it and stopping transmission.

The U.S. Centers for Disease Control and Prevention has warned Americans to be careful with cleaning products in their rush to use cleaners and disinfectants, which have been snapped up from store shelves and are still hard to find at many retailers. Poisonings related to cleaners and disinfectants rose significantly in March, according to the CDC. In one case, a woman was sent to the hospital after filling her sink with bleach solution, vinegar and hot water to soak her vegetables.

He tries to bring Birx into the mix and then note his response when confronted about the whole heat and light thing:

You know, hes just asking. Lighten up!

All of this is, of course, quite bizarre and I am leaning heavily on the absurdity angle (as this is very much a laugh lest you cry situation). But, good grief, we in the middle of a global pandemic with no clear end in sight and with over 44,000 Americans dead, and the president is spitballing light therapy and the potential use of cleaners in the human body to fight Covid-19. And worse, many, many of my fellow Americans think he is doing a good job.

BTW, if we think that heat and humidity will be our salvation, the following story popped up while I was writing this (via the NYT): Ecuadors Death Toll During Outbreak Is Among the Worst in the World.

With bodies abandoned on sidewalks, slumped in wheelchairs, packed into cardboard coffins and stacked by the hundreds in morgues, it is clear that Ecuador has been devastated by the coronavirus.

But the epidemic is even worse than many people in the country realize.The death toll in Ecuador during the outbreak was 15 times higher than the official number of Covid-19 deaths reported by the government, according to an analysis of mortality data by The New York Times.The numbers suggest that the South American country is suffering one of the worst outbreaks in the world.

[]

There has been a surge of infections in the province that includes Ecuadors business capital, Guayaquil, where residents are thought to have brought the virus home after visiting Spain.In Guayaquil, fatalities during the first two weeks of April were eight times higher than usual, the data indicates a far greater rise than that of New York City, where fatalities were four times higher in recent weeks.

Guayaquil has a decidedly tropical climate

PS. Yes, the use of light to kill an infestation was a plot point in the Star Trek TOS episode, Operation: Annihilate:

Read more:
I'm Sorry, What? - Outside The Beltway - Mobile Edition

Read More...

COVID-19 and civil aviation – The Lawyer’s Daily

Tuesday, April 21st, 2020

Severe acute respiratory syndrome, coronavirus 2, SARS-CoV-2 (COVID-19), a betacoronavirus, with a fulminant atypical pneumonia presentation, sharing a high sequence identity with that of SARS-CoV-1 and bat-SARS-like coronavirus the global pandemic of 2020 has affected every continent except Antarctica where no humans live.

The convention on International Civil Aviation (Convention), International Civil Aviation Organization (ICAO), U.S., Regulation (EC) No. 216/2008, Regulation (EC) No. 216/2008, Canadian and other law must adapt to reflect the 21st century. Airworthiness is the measure of an aircraft being suitable for a safe flight. Aerosol and fomite (objects or materials that are likely to carry infection, such as elevator buttons or bathroom taps) transmission of COVID-19 is plausible because viruses can propagate or function properly and are infectious in aerosols for hours and on surfaces for days.

Dr. Tedros Adhanom Ghebreyesus, the World Health Organizations (WHO) Director General and Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, indicated that the RNA viruses emanated from China, have mutated and are transmitted from human to human as they are what we call RNA viruses, or those that have mainly RNA as their genetic material (one being COVID-19), in comparison to DNA. RNA viruses mutate constantly and do not have the mechanisms to correct these mistakes like those of human cells, which replicate with DNA. The mistakes appear in the genetic sequence coding for the corona protein with a total length of 1,273 amino acids showing 27 amino acid substitutions (a mutation).

Since 2002, COVID-19 has been a perfect example where multiple genes of a virus have exceptionally high mutation rates since its origin, causing it to be more severe in some cases or transmit more easily and depending on the temperature. According to scientists, the coronavirus thrives in cold and dry conditions and may not be a stranger next winter if it wanes over the summer.

Not long ago, accurate RNA detection was decisive in the diagnosis of COVID-19 through the COVID-19 RT-PCR test, a real time reverse transcription polymerase chain reaction, for the qualitative detection of the SARS-CoV-2 RNA, and next generation sequencing has facilitated the identification of the pathogen. The amino acid sequence of COVID-19 is different from other coronaviruses, particularly in the regions of 1ab polyprotein and surface glycoprotein or S protein.

The first novel coronavirus genome sequence of COVID-19 was discovered on Jan. 10 and was deposited in the GenBank database and uploaded to the Global Initiative on Sharing All Influenza Data. By Jan. 20, Thailand, Japan and South Korea confirmed all cases were exported from China. France reported its first case on Jan. 24 and Germany reported cases related to an individual visiting from China.

Brazilian scientists conducted preliminary studies, which showed the virus in Brazil to be different from the one observed in Wuhan, China by three mutations, two of which draw the virus close to the strain detected in the Bavarian region of Germany.

COVID-19 spread so quickly throughout Wuhan because it is a densely populated area. With international business travellers and tourists leaving China, individuals asymptomatic or ill with the virus transmitted to others on airplanes, which were densely packed and often delayed, and with many having no ventilation system. When airplanes were ventilated, the bleed air supply was a mixture of fresh, cold air fromoutside and recirculated air from the cabin. The airworthiness in aircrafts were compromised, violating the U.S. Code of Federal Regulations, 14 CFR s. 91.7 civil aircraft airworthiness: a) No person may operate a civil aircraft unless it is in an airworthy condition.

The Canadian counterpart is the Canadian Aviation Regulations, SOR/96-433 (s. 521.30), which states: The Minister shall establish, in respect of an aeronautical product, a certification basis consisting of: a) subject to subsections (2) and (5), the applicable standards of airworthiness referred to in s. 521.31 that are in force on the date of application for the type certificate.

Regulation (EC) No. 216/2008 of the European Parliament and of the Council of Feb. 20, 2008 included the common rules in the field of civil aviation and established a European Aviation Safety Agency, repealing Council Directive 91/670/EEC, Regulation (EC) No. 1592/2002 and Directive 2004/36/E. Currently, the United Kingdom is a member state of the European Aviation Safety Agency, Article 20, until Dec. 31, when the U.K. Civil Aviation Authority will assume responsibility over the airworthiness of aircraft in the U.K.

Aside from human to human transmission of the virus, which mainly occurs through saliva droplets and direct and indirect contact with surfaces, Dr.Neeltje van Doremalen et al have raised a legitimate concern over aerosol and surface transmission in a study published by the New England Journal of Medicine titled Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.

Their data comprised 10 experimental conditions with the two viruses in five environmental conditions aerosols, plastic, stainless steel, copper and cardboard. The strength to stand or endure SARS-CoV-2 was equivalent to that of SARS-CoV-1 under the study of van Doremalen et al indicating differences of epidemiologic characteristics of SARS-CoV-2 and the latter, which probably come about from other factors such as high viral burden (high numerical expression of the virus quantity in a given volume) in the upper respiratory tract (nose and nasal passages, paranasal sinuses, the pharynx and part of the larynx) and the possibility of individuals affected with asymptomatic SARS-CoV-2 to shed and transmit the virus.

The Convention on International Civil Aviation (Chicago Convention) received its 26th ratification on March 5, 1947. After ratification, the ICAO was born, on April 4, 1947, becoming a specialized agency of the United Nations connected to the Economic and Social Council.

Although Article 14 of the convention defines COVID-19 as a communicable disease, thereby dealing with the prevention of the spread of disease, Article 35, which reflects cargo restrictions, speaks of munitions. In the Cambridge Dictionary, munitions are defined as military weapons guns and bombs as well as implements that take into account a tool or other piece of equipment for doing work or implements of work, which include arms, ammunition, weaponry and defence systems. Blacks Law Dictionary, international law and U.S. statutes do not include communicable diseases under munitions of war.

Given the pandemic, Article 37(e) adoption of international standards and procedures requires a change to reflect certain issues in countries.

With the significant number of cases and the severe implications of the virus, COVID-19 is the biggest public health threat in the world. The Convention on International Civil Aviation, the ICAO, as well as U.S., U.K., Canadian and other law, must give due consideration to the new implications of coronaviruses.

Esther Carenza is a senior law clerk who works primarily in the area of legal-medical research and as a legal-medical consultant. She was also a mentor-supervisor for the Medico-Legal Society of Toronto project at the University of Toronto, Faculty of Law and Osgoode Hall Law School. E-mail her atecarenza1@gmail.com.

Photo credit / blacklight_traceISTOCKPHOTO.COM

Interested in writing for us? To learn more about how you can add your voice toThe Lawyers Daily,contact Analysis Editor Peter Carter atpeter.carter@lexisnexis.caor call 647-776-6740.

The rest is here:
COVID-19 and civil aviation - The Lawyer's Daily

Read More...

6 Things Experts Look For In A High-Quality Hemp Oil – mindbodygreen.com

Tuesday, April 21st, 2020

According to Carl Germano, R.D., CNS, CDN, the author of Road to Ananda: Simple Guide to the Endocannabinoid System, Hemp Phytocannabinoids/CBD, and Your Health, the use of pesticides, herbicides, and genetic modification is not uncommon in the hemp industry. Plus, hemp is a bioaccumulator, meaning it's very efficient at removing toxins and pollutants from the air, water, and soil. (The plant is so good at this that it's actually being used to help clean up dirty environments.) This means that if your hemp is not grown and processed carefully, you might be getting toxins in your extract. Look for an organic, non-GMO product that's been certified from a third party and tested for heavy metals.

Also, if not stored and handled properly, hemp is prone to growing certain kinds of fungi that can produce aflatoxin, a substance that can cause liver damage and other health issues. Yet another reason to buy from a reputable brand that handles the crop properly and tests for aflatoxin.

Read the rest here:
6 Things Experts Look For In A High-Quality Hemp Oil - mindbodygreen.com

Read More...

How the Pandemic Will End – The Atlantic

Wednesday, March 25th, 2020

Editors Note: The Atlantic is making vital coverage of the coronavirus available to all readers. Find the collection here.

Three months ago, no one knew that SARS-CoV-2 existed. Now the virus has spread to almost every country, infecting at least 446,000 people whom we know about, and many more whom we do not. It has crashed economies and broken health-care systems, filled hospitals and emptied public spaces. It has separated people from their workplaces and their friends. It has disrupted modern society on a scale that most living people have never witnessed. Soon, most everyone in the United States will know someone who has been infected. Like World War II or the 9/11 attacks, this pandemic has already imprinted itself upon the nations psyche.

A global pandemic of this scale was inevitable. In recent years, hundreds of health experts have written books, white papers, and op-eds warning of the possibility. Bill Gates has been telling anyone who would listen, including the 18 million viewers of his TED Talk. In 2018, I wrote a story for The Atlantic arguing that America was not ready for the pandemic that would eventually come. In October, the Johns Hopkins Center for Health Security war-gamed what might happen if a new coronavirus swept the globe. And then one did. Hypotheticals became reality. What if? became Now what?

So, now what? In the late hours of last Wednesday, which now feels like the distant past, I was talking about the pandemic with a pregnant friend who was days away from her due date. We realized that her child might be one of the first of a new cohort who are born into a society profoundly altered by COVID-19. We decided to call them Generation C.

As well see, Gen Cs lives will be shaped by the choices made in the coming weeks, and by the losses we suffer as a result. But first, a brief reckoning. On the Global Health Security Index, a report card that grades every country on its pandemic preparedness, the United States has a score of 83.5the worlds highest. Rich, strong, developed, America is supposed to be the readiest of nations. That illusion has been shattered. Despite months of advance warning as the virus spread in other countries, when America was finally tested by COVID-19, it failed.

Anne Applebaum: The coronavirus called Americas bluff

No matter what, a virus [like SARS-CoV-2] was going to test the resilience of even the most well-equipped health systems, says Nahid Bhadelia, an infectious-diseases physician at the Boston University School of Medicine. More transmissible and fatal than seasonal influenza, the new coronavirus is also stealthier, spreading from one host to another for several days before triggering obvious symptoms. To contain such a pathogen, nations must develop a test and use it to identify infected people, isolate them, and trace those theyve had contact with. That is what South Korea, Singapore, and Hong Kong did to tremendous effect. It is what the United States did not.

As my colleagues Alexis Madrigal and Robinson Meyer have reported, the Centers for Disease Control and Prevention developed and distributed a faulty test in February. Independent labs created alternatives, but were mired in bureaucracy from the FDA. In a crucial month when the American caseload shot into the tens of thousands, only hundreds of people were tested. That a biomedical powerhouse like the U.S. should so thoroughly fail to create a very simple diagnostic test was, quite literally, unimaginable. Im not aware of any simulations that I or others have run where we [considered] a failure of testing, says Alexandra Phelan of Georgetown University, who works on legal and policy issues related to infectious diseases.

The testing fiasco was the original sin of Americas pandemic failure, the single flaw that undermined every other countermeasure. If the country could have accurately tracked the spread of the virus, hospitals could have executed their pandemic plans, girding themselves by allocating treatment rooms, ordering extra supplies, tagging in personnel, or assigning specific facilities to deal with COVID-19 cases. None of that happened. Instead, a health-care system that already runs close to full capacity, and that was already challenged by a severe flu season, was suddenly faced with a virus that had been left to spread, untracked, through communities around the country. Overstretched hospitals became overwhelmed. Basic protective equipment, such as masks, gowns, and gloves, began to run out. Beds will soon follow, as will the ventilators that provide oxygen to patients whose lungs are besieged by the virus.

Read: The people ignoring social distancing

With little room to surge during a crisis, Americas health-care system operates on the assumption that unaffected states can help beleaguered ones in an emergency. That ethic works for localized disasters such as hurricanes or wildfires, but not for a pandemic that is now in all 50 states. Cooperation has given way to competition; some worried hospitals have bought out large quantities of supplies, in the way that panicked consumers have bought out toilet paper.

Partly, thats because the White House is a ghost town of scientific expertise. A pandemic-preparedness office that was part of the National Security Council was dissolved in 2018. On January 28, Luciana Borio, who was part of that team, urged the government to act now to prevent an American epidemic, and specifically to work with the private sector to develop fast, easy diagnostic tests. But with the office shuttered, those warnings were published in The Wall Street Journal, rather than spoken into the presidents ear. Instead of springing into action, America sat idle.

Derek Thompson: America is acting like a failed state

Rudderless, blindsided, lethargic, and uncoordinated, America has mishandled the COVID-19 crisis to a substantially worse degree than what every health expert Ive spoken with had feared. Much worse, said Ron Klain, who coordinated the U.S. response to the West African Ebola outbreak in 2014. Beyond any expectations we had, said Lauren Sauer, who works on disaster preparedness at Johns Hopkins Medicine. As an American, Im horrified, said Seth Berkley, who heads Gavi, the Vaccine Alliance. The U.S. may end up with the worst outbreak in the industrialized world.

Having fallen behind, it will be difficultbut not impossiblefor the United States to catch up. To an extent, the near-term future is set because COVID-19 is a slow and long illness. People who were infected several days ago will only start showing symptoms now, even if they isolated themselves in the meantime. Some of those people will enter intensive-care units in early April. As of last weekend, the nation had 17,000 confirmed cases, but the actual number was probably somewhere between 60,000 and 245,000. Numbers are now starting to rise exponentially: As of Wednesday morning, the official case count was 54,000, and the actual case count is unknown. Health-care workers are already seeing worrying signs: dwindling equipment, growing numbers of patients, and doctors and nurses who are themselves becoming infected.

Italy and Spain offer grim warnings about the future. Hospitals are out of room, supplies, and staff. Unable to treat or save everyone, doctors have been forced into the unthinkable: rationing care to patients who are most likely to survive, while letting others die. The U.S. has fewer hospital beds per capita than Italy. A study released by a team at Imperial College London concluded that if the pandemic is left unchecked, those beds will all be full by late April. By the end of June, for every available critical-care bed, there will be roughly 15 COVID-19 patients in need of one. By the end of the summer, the pandemic will have directly killed 2.2 million Americans, notwithstanding those who will indirectly die as hospitals are unable to care for the usual slew of heart attacks, strokes, and car accidents. This is the worst-case scenario. To avert it, four things need to happenand quickly.

Read: All the presidents lies about the coronavirus

The first and most important is to rapidly produce masks, gloves, and other personal protective equipment. If health-care workers cant stay healthy, the rest of the response will collapse. In some places, stockpiles are already so low that doctors are reusing masks between patients, calling for donations from the public, or sewing their own homemade alternatives. These shortages are happening because medical supplies are made-to-order and depend on byzantine international supply chains that are currently straining and snapping. Hubei province in China, the epicenter of the pandemic, was also a manufacturing center of medical masks.

In the U.S., the Strategic National Stockpilea national larder of medical equipmentis already being deployed, especially to the hardest-hit states. The stockpile is not inexhaustible, but it can buy some time. Donald Trump could use that time to invoke the Defense Production Act, launching a wartime effort in which American manufacturers switch to making medical equipment. But after invoking the act last Wednesday, Trump has failed to actually use it, reportedly due to lobbying from the U.S. Chamber of Commerce and heads of major corporations.

Some manufacturers are already rising to the challenge, but their efforts are piecemeal and unevenly distributed. One day, well wake up to a story of doctors in City X who are operating with bandanas, and a closet in City Y with masks piled into it, says Ali Khan, the dean of public health at the University of Nebraska Medical Center. A massive logistics and supply-chain operation [is] now needed across the country, says Thomas Inglesby of Johns Hopkins Bloomberg School of Public Health. That cant be managed by small and inexperienced teams scattered throughout the White House. The solution, he says, is to tag in the Defense Logistics Agencya 26,000-person group that prepares the U.S. military for overseas operations and that has assisted in past public-health crises, including the 2014 Ebola outbreak.

This agency can also coordinate the second pressing need: a massive rollout of COVID-19 tests. Those tests have been slow to arrive because of five separate shortages: of masks to protect people administering the tests; of nasopharyngeal swabs for collecting viral samples; of extraction kits for pulling the viruss genetic material out of the samples; of chemical reagents that are part of those kits; and of trained people who can give the tests. Many of these shortages are, again, due to strained supply chains. The U.S. relies on three manufacturers for extraction reagents, providing redundancy in case any of them failsbut all of them failed in the face of unprecedented global demand. Meanwhile, Lombardy, Italy, the hardest-hit place in Europe, houses one of the largest manufacturers of nasopharyngeal swabs.

Read: Why the coronavirus has been so successful

Some shortages are being addressed. The FDA is now moving quickly to approve tests developed by private labs. At least one can deliver results in less than an hour, potentially allowing doctors to know if the patient in front of them has COVID-19. The country is adding capacity on a daily basis, says Kelly Wroblewski of the Association of Public Health Laboratories.

On March 6, Trump said that anyone who wants a test can get a test. That was (and still is) untrue, and his own officials were quick to correct him. Regardless, anxious people still flooded into hospitals, seeking tests that did not exist. People wanted to be tested even if they werent symptomatic, or if they sat next to someone with a cough, says Saskia Popescu of George Mason University, who works to prepare hospitals for pandemics. Others just had colds, but doctors still had to use masks to examine them, burning through their already dwindling supplies. It really stressed the health-care system, Popescu says. Even now, as capacity expands, tests must be used carefully. The first priority, says Marc Lipsitch of Harvard, is to test health-care workers and hospitalized patients, allowing hospitals to quell any ongoing fires. Only later, once the immediate crisis is slowing, should tests be deployed in a more widespread way. This isnt just going to be: Lets get the tests out there! Inglesby says.

These measures will take time, during which the pandemic will either accelerate beyond the capacity of the health system or slow to containable levels. Its courseand the nations fatenow depends on the third need, which is social distancing. Think of it this way: There are now only two groups of Americans. Group A includes everyone involved in the medical response, whether thats treating patients, running tests, or manufacturing supplies. Group B includes everyone else, and their job is to buy Group A more time. Group B must now flatten the curve by physically isolating themselves from other people to cut off chains of transmission. Given the slow fuse of COVID-19, to forestall the future collapse of the health-care system, these seemingly drastic steps must be taken immediately, before they feel proportionate, and they must continue for several weeks.

Juliette Kayyem: The crisis could last 18 months. Be prepared.

Persuading a country to voluntarily stay at home is not easy, and without clear guidelines from the White House, mayors, governors, and business owners have been forced to take their own steps. Some states have banned large gatherings or closed schools and restaurants. At least 21 have now instituted some form of mandatory quarantine, compelling people to stay at home. And yet many citizens continue to crowd into public spaces.

In these moments, when the good of all hinges on the sacrifices of many, clear coordination mattersthe fourth urgent need. The importance of social distancing must be impressed upon a public who must also be reassured and informed. Instead, Trump has repeatedly played down the problem, telling America that we have it very well under control when we do not, and that cases were going to be down to close to zero when they were rising. In some cases, as with his claims about ubiquitous testing, his misleading gaffes have deepened the crisis. He has even touted unproven medications.

Away from the White House press room, Trump has apparently been listening to Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases. Fauci has advised every president since Ronald Reagan on new epidemics, and now sits on the COVID-19 task force that meets with Trump roughly every other day. Hes got his own style, lets leave it at that, Fauci told me, but any kind of recommendation that I have made thus far, the substance of it, he has listened to everything.

Read: Grocery stores are the coronavirus tipping point

But Trump already seems to be wavering. In recent days, he has signaled that he is prepared to backtrack on social-distancing policies in a bid to protect the economy. Pundits and business leaders have used similar rhetoric, arguing that high-risk people, such as the elderly, could be protected while lower-risk people are allowed to go back to work. Such thinking is seductive, but flawed. It overestimates our ability to assess a persons risk, and to somehow wall off the high-risk people from the rest of society. It underestimates how badly the virus can hit low-risk groups, and how thoroughly hospitals will be overwhelmed if even just younger demographics are falling sick.

A recent analysis from the University of Pennsylvania estimated that even if social-distancing measures can reduce infection rates by 95 percent, 960,000 Americans will still need intensive care. There are only about 180,000 ventilators in the U.S. and, more pertinently, only enough respiratory therapists and critical-care staff to safely look after 100,000 ventilated patients. Abandoning social distancing would be foolish. Abandoning it now, when tests and protective equipment are still scarce, would be catastrophic.

Read: Americas hospitals have never experienced anything like this

If Trump stays the course, if Americans adhere to social distancing, if testing can be rolled out, and if enough masks can be produced, there is a chance that the country can still avert the worst predictions about COVID-19, and at least temporarily bring the pandemic under control. No one knows how long that will take, but it wont be quick. It could be anywhere from four to six weeks to up to three months, Fauci said, but I dont have great confidence in that range.

Even a perfect response wont end the pandemic. As long as the virus persists somewhere, theres a chance that one infected traveler will reignite fresh sparks in countries that have already extinguished their fires. This is already happening in China, Singapore, and other Asian countries that briefly seemed to have the virus under control. Under these conditions, there are three possible endgames: one thats very unlikely, one thats very dangerous, and one thats very long.

The first is that every nation manages to simultaneously bring the virus to heel, as with the original SARS in 2003. Given how widespread the coronavirus pandemic is, and how badly many countries are faring, the odds of worldwide synchronous control seem vanishingly small.

The second is that the virus does what past flu pandemics have done: It burns through the world and leaves behind enough immune survivors that it eventually struggles to find viable hosts. This herd immunity scenario would be quick, and thus tempting. But it would also come at a terrible cost: SARS-CoV-2 is more transmissible and fatal than the flu, and it would likely leave behind many millions of corpses and a trail of devastated health systems. The United Kingdom initially seemed to consider this herd-immunity strategy, before backtracking when models revealed the dire consequences. The U.S. now seems to be considering it too.

Read: What will you do if you start coughing?

The third scenario is that the world plays a protracted game of whack-a-mole with the virus, stamping out outbreaks here and there until a vaccine can be produced. This is the best option, but also the longest and most complicated.

It depends, for a start, on making a vaccine. If this were a flu pandemic, that would be easier. The world is experienced at making flu vaccines and does so every year. But there are no existing vaccines for coronavirusesuntil now, these viruses seemed to cause diseases that were mild or rareso researchers must start from scratch. The first steps have been impressively quick. Last Monday, a possible vaccine created by Moderna and the National Institutes of Health went into early clinical testing. That marks a 63-day gap between scientists sequencing the viruss genes for the first time and doctors injecting a vaccine candidate into a persons arm. Its overwhelmingly the world record, Fauci said.

But its also the fastest step among many subsequent slow ones. The initial trial will simply tell researchers if the vaccine seems safe, and if it can actually mobilize the immune system. Researchers will then need to check that it actually prevents infection from SARS-CoV-2. Theyll need to do animal tests and large-scale trials to ensure that the vaccine doesnt cause severe side effects. Theyll need to work out what dose is required, how many shots people need, if the vaccine works in elderly people, and if it requires other chemicals to boost its effectiveness.

Even if it works, they dont have an easy way to manufacture it at a massive scale, said Seth Berkley of Gavi. Thats because Moderna is using a new approach to vaccination. Existing vaccines work by providing the body with inactivated or fragmented viruses, allowing the immune system to prep its defenses ahead of time. By contrast, Modernas vaccine comprises a sliver of SARS-CoV-2s genetic materialits RNA. The idea is that the body can use this sliver to build its own viral fragments, which would then form the basis of the immune systems preparations. This approach works in animals, but is unproven in humans. By contrast, French scientists are trying to modify the existing measles vaccine using fragments of the new coronavirus. The advantage of that is that if we needed hundreds of doses tomorrow, a lot of plants in the world know how to do it, Berkley said. No matter which strategy is faster, Berkley and others estimate that it will take 12 to 18 months to develop a proven vaccine, and then longer still to make it, ship it, and inject it into peoples arms.

Read: COVID-19 vaccines are coming, but theyre not what you think

Its likely, then, that the new coronavirus will be a lingering part of American life for at least a year, if not much longer. If the current round of social-distancing measures works, the pandemic may ebb enough for things to return to a semblance of normalcy. Offices could fill and bars could bustle. Schools could reopen and friends could reunite. But as the status quo returns, so too will the virus. This doesnt mean that society must be on continuous lockdown until 2022. But we need to be prepared to do multiple periods of social distancing, says Stephen Kissler of Harvard.

Much about the coming years, including the frequency, duration, and timing of social upheavals, depends on two properties of the virus, both of which are currently unknown. First: seasonality. Coronaviruses tend to be winter infections that wane or disappear in the summer. That may also be true for SARS-CoV-2, but seasonal variations might not sufficiently slow the virus when it has so many immunologically naive hosts to infect. Much of the world is waiting anxiously to see whatif anythingthe summer does to transmission in the Northern Hemisphere, says Maia Majumder of Harvard Medical School and Boston Childrens Hospital.

Second: duration of immunity. When people are infected by the milder human coronaviruses that cause cold-like symptoms, they remain immune for less than a year. By contrast, the few who were infected by the original SARS virus, which was far more severe, stayed immune for much longer. Assuming that SARS-CoV-2 lies somewhere in the middle, people who recover from their encounters might be protected for a couple of years. To confirm that, scientists will need to develop accurate serological tests, which look for the antibodies that confer immunity. Theyll also need to confirm that such antibodies actually stop people from catching or spreading the virus. If so, immune citizens can return to work, care for the vulnerable, and anchor the economy during bouts of social distancing.

Scientists can use the periods between those bouts to develop antiviral drugsalthough such drugs are rarely panaceas, and come with possible side effects and the risk of resistance. Hospitals can stockpile the necessary supplies. Testing kits can be widely distributed to catch the viruss return as quickly as possible. Theres no reason that the U.S. should let SARS-CoV-2 catch it unawares again, and thus no reason that social-distancing measures need to be deployed as broadly and heavy-handedly as they now must be. As Aaron E. Carroll and Ashish Jha recently wrote, We can keep schools and businesses open as much as possible, closing them quickly when suppression fails, then opening them back up again once the infected are identified and isolated. Instead of playing defense, we could play more offense.

Whether through accumulating herd immunity or the long-awaited arrival of a vaccine, the virus will find spreading explosively more and more difficult. Its unlikely to disappear entirely. The vaccine may need to be updated as the virus changes, and people may need to get revaccinated on a regular basis, as they currently do for the flu. Models suggest that the virus might simmer around the world, triggering epidemics every few years or so. But my hope and expectation is that the severity would decline, and there would be less societal upheaval, Kissler says. In this future, COVID-19 may become like the flu is todaya recurring scourge of winter. Perhaps it will eventually become so mundane that even though a vaccine exists, large swaths of Gen C wont bother getting it, forgetting how dramatically their world was molded by its absence.

The cost of reaching that point, with as few deaths as possible, will be enormous. As my colleague Annie Lowrey wrote, the economy is experiencing a shock more sudden and severe than anyone alive has ever experienced. About one in five people in the United States have lost working hours or jobs. Hotels are empty. Airlines are grounding flights. Restaurants and other small businesses are closing. Inequalities will widen: People with low incomes will be hardest-hit by social-distancing measures, and most likely to have the chronic health conditions that increase their risk of severe infections. Diseases have destabilized cities and societies many times over, but it hasnt happened in this country in a very long time, or to quite the extent that were seeing now, says Elena Conis, a historian of medicine at UC Berkeley. Were far more urban and metropolitan. We have more people traveling great distances and living far from family and work.

After infections begin ebbing, a secondary pandemic of mental-health problems will follow. At a moment of profound dread and uncertainty, people are being cut off from soothing human contact. Hugs, handshakes, and other social rituals are now tinged with danger. People with anxiety or obsessive-compulsive disorder are struggling. Elderly people, who are already excluded from much of public life, are being asked to distance themselves even further, deepening their loneliness. Asian people are suffering racist insults, fueled by a president who insists on labeling the new coronavirus the Chinese virus. Incidents of domestic violence and child abuse are likely to spike as people are forced to stay in unsafe homes. Children, whose bodies are mostly spared by the virus, may endure mental trauma that stays with them into adulthood.

Read: The kids arent all right

After the pandemic, people who recover from COVID-19 might be shunned and stigmatized, as were survivors of Ebola, SARS, and HIV. Health-care workers will take time to heal: One to two years after SARS hit Toronto, people who dealt with the outbreak were still less productive and more likely to be experiencing burnout and post-traumatic stress. People who went through long bouts of quarantine will carry the scars of their experience. My colleagues in Wuhan note that some people there now refuse to leave their homes and have developed agoraphobia, says Steven Taylor of the University of British Columbia, who wrote The Psychology of Pandemics.

But there is also the potential for a much better world after we get through this trauma, says Richard Danzig of the Center for a New American Security. Already, communities are finding new ways of coming together, even as they must stay apart. Attitudes to health may also change for the better. The rise of HIV and AIDS completely changed sexual behavior among young people who were coming into sexual maturity at the height of the epidemic, Conis says. The use of condoms became normalized. Testing for STDs became mainstream. Similarly, washing your hands for 20 seconds, a habit that has historically been hard to enshrine even in hospitals, may be one of those behaviors that we become so accustomed to in the course of this outbreak that we dont think about them, Conis adds.

Pandemics can also catalyze social change. People, businesses, and institutions have been remarkably quick to adopt or call for practices that they might once have dragged their heels on, including working from home, conference-calling to accommodate people with disabilities, proper sick leave, and flexible child-care arrangements. This is the first time in my lifetime that Ive heard someone say, Oh, if youre sick, stay home, says Adia Benton, an anthropologist at Northwestern University. Perhaps the nation will learn that preparedness isnt just about masks, vaccines, and tests, but also about fair labor policies and a stable and equal health-care system. Perhaps it will appreciate that health-care workers and public-health specialists compose Americas social immune system, and that this system has been suppressed.

Aspects of Americas identity may need rethinking after COVID-19. Many of the countrys values have seemed to work against it during the pandemic. Its individualism, exceptionalism, and tendency to equate doing whatever you want with an act of resistance meant that when it came time to save lives and stay indoors, some people flocked to bars and clubs. Having internalized years of anti-terrorism messaging following 9/11, Americans resolved to not live in fear. But SARS-CoV-2 has no interest in their terror, only their cells.

Years of isolationist rhetoric had consequences too. Citizens who saw China as a distant, different place, where bats are edible and authoritarianism is acceptable, failed to consider that they would be next or that they wouldnt be ready. (Chinas response to this crisis had its own problems, but thats for another time.) People believed the rhetoric that containment would work, says Wendy Parmet, who studies law and public health at Northeastern University. We keep them out, and well be okay. When you have a body politic that buys into these ideas of isolationism and ethnonationalism, youre especially vulnerable when a pandemic hits.

Graeme Wood: The Chinese virus is a test. Dont fail it.

Veterans of past epidemics have long warned that American society is trapped in a cycle of panic and neglect. After every crisisanthrax, SARS, flu, Ebolaattention is paid and investments are made. But after short periods of peacetime, memories fade and budgets dwindle. This trend transcends red and blue administrations. When a new normal sets in, the abnormal once again becomes unimaginable. But there is reason to think that COVID-19 might be a disaster that leads to more radical and lasting change.

The other major epidemics of recent decades either barely affected the U.S. (SARS, MERS, Ebola), were milder than expected (H1N1 flu in 2009), or were mostly limited to specific groups of people (Zika, HIV). The COVID-19 pandemic, by contrast, is affecting everyone directly, changing the nature of their everyday life. That distinguishes it not only from other diseases, but also from the other systemic challenges of our time. When an administration prevaricates on climate change, the effects wont be felt for years, and even then will be hard to parse. Its different when a president says that everyone can get a test, and one day later, everyone cannot. Pandemics are democratizing experiences. People whose privilege and power would normally shield them from a crisis are facing quarantines, testing positive, and losing loved ones. Senators are falling sick. The consequences of defunding public-health agencies, losing expertise, and stretching hospitals are no longer manifesting as angry opinion pieces, but as faltering lungs.

After 9/11, the world focused on counterterrorism. After COVID-19, attention may shift to public health. Expect to see a spike in funding for virology and vaccinology, a surge in students applying to public-health programs, and more domestic production of medical supplies. Expect pandemics to top the agenda at the United Nations General Assembly. Anthony Fauci is now a household name. Regular people who think easily about what a policewoman or firefighter does finally get what an epidemiologist does, says Monica Schoch-Spana, a medical anthropologist at the Johns Hopkins Center for Health Security.

Such changes, in themselves, might protect the world from the next inevitable disease. The countries that had lived through SARS had a public consciousness about this that allowed them to leap into action, said Ron Klain, the former Ebola czar. The most commonly uttered sentence in America at the moment is, Ive never seen something like this before. That wasnt a sentence anyone in Hong Kong uttered. For the U.S., and for the world, its abundantly, viscerally clear what a pandemic can do.

The lessons that America draws from this experience are hard to predict, especially at a time when online algorithms and partisan broadcasters only serve news that aligns with their audiences preconceptions. Such dynamics will be pivotal in the coming months, says Ilan Goldenberg, a foreign-policy expert at the Center for a New American Security. The transitions after World War II or 9/11 were not about a bunch of new ideas, he says. The ideas are out there, but the debates will be more acute over the next few months because of the fluidity of the moment and willingness of the American public to accept big, massive changes.

One could easily conceive of a world in which most of the nation believes that America defeated COVID-19. Despite his many lapses, Trumps approval rating has surged. Imagine that he succeeds in diverting blame for the crisis to China, casting it as the villain and America as the resilient hero. During the second term of his presidency, the U.S. turns further inward and pulls out of NATO and other international alliances, builds actual and figurative walls, and disinvests in other nations. As Gen C grows up, foreign plagues replace communists and terrorists as the new generational threat.

One could also envisage a future in which America learns a different lesson. A communal spirit, ironically born through social distancing, causes people to turn outward, to neighbors both foreign and domestic. The election of November 2020 becomes a repudiation of America first politics. The nation pivots, as it did after World War II, from isolationism to international cooperation. Buoyed by steady investments and an influx of the brightest minds, the health-care workforce surges. Gen C kids write school essays about growing up to be epidemiologists. Public health becomes the centerpiece of foreign policy. The U.S. leads a new global partnership focused on solving challenges like pandemics and climate change.

In 2030, SARS-CoV-3 emerges from nowhere, and is brought to heel within a month.

Read more:
How the Pandemic Will End - The Atlantic

Read More...

‘Slow The Spread’: All Americans Summoned in COVID-19 Response Pascack Press & Northern Valley Press – Pascack Press & Northern Valley Press

Wednesday, March 25th, 2020

President Donald Trump is optimistic a vaccine for the novel Coronavirus COVID-19 may soon be forthcoming, but his White House Coronavirus response coordinator says the only thing we have right now is the amazing ingenuity and compassion of the American people.

WASHINGTON, D.C.America is at war against the novel Coronavirus COVID-19, President Donald Trump said March 18.

The Federal Emergency Management Agency is at a level-one response nationwide, withconfirmed COVID-19 cases in all 50 states.

On Monday, March 16, Trump and the Centers for Disease Control announced 15 days to slow the spread by practicing social distancing, listening to state and local authorities, and staying home if sick, or if someone in a household has tested positive or is displaying symptoms.

All of our experts continue to believe that if every American will do their part and embrace and put into practice these principles that we can significantly limit the reach of the Coronavirus in the weeks and months ahead, Vice President Mike Pence said March 18.

The genetic sequence of the virus was first published in January, and human trials for vaccine have been reached just eight weeks later, the fastest development in history, Trump said.

But since we dont currently have a vaccine or a therapeutic to address this novel Coronavirus,the only thing we have right now is the amazing ingenuity and compassion of the American people, said Amb. Deborah Birx, the White Houses Coronavirus response coordinator.

Trump deployed the USNS Comforta U.S. Navy hospital ship with about 1,000 rooms and operating roomsto New York harbor, adjacent to New York City, to expand hospital capacity amid what some have warned could be a crushing wave of yet-to-be-diagnosed new cases. New York Gov. Andrew Cuomo earlier raised alarms that his states hospital capacity is not prepared to handle a surge of critically ill patients, and New Jersey and all states have mirror concerns.

Trump said the country is working to acquired more ventilators and medical supplies for front-line emergency personnel and hospitals.

Its all over the world, said Trump, of COVID-19. Itsincredible whats happened in such a short time.

Trump said, August, could be July, maybe longer than that, when asked to speculate on when society may return to normalcy.

Financial markets have plummeted given the circumstances, with the Dow Jones Industrial Average dropping more than 10,000 points and wiping out all gains under the Trump presidency.

The White House is seeking $500 billion in direct payments to taxpayers and President Trump invoked a wartime law to press companies to make medical supplies, The New York Times reports.

Its a tough situation[Six weeks ago] we had the besteconomy weve ever had, Trump said, then you have to close it down to defeat this enemy.

If everyone makes this change, or these critical changes and sacrifices now, we will rally together as one nation and we will defeat the virus. And were going to have a big celebration all together, Trump said.

For updates: cdc.gov/coronavirus; or http://www.nj.gov/health.

See more here:
'Slow The Spread': All Americans Summoned in COVID-19 Response Pascack Press & Northern Valley Press - Pascack Press & Northern Valley Press

Read More...

Next-Generation Sequencing Market 2020: Product Types and Application, Massive Growth, Demand Insights, Opportunities Assessment and Forecast 2025 -…

Wednesday, March 25th, 2020

Global Next Generation Sequencing (NGS) Market, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Re-sequencing, and Others), by Application (Drug Discovery, Personalized Medicine and Genetic Screening, Disease Diagnosis, Agriculture and Animal Research, and Others), by End User (Hospital, Research Centers, Pharma and Biotech Firms, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is projected to exhibit a healthy CAGR over the forecast period (2019 2025)

Get Research Insights @Next Generation Sequencing Market Size 2019-2025

Reducing NGS capital cost associated with declining sequencing cost, developments in NGS platforms and developing scenario of reimbursement and regulatory for diagnostic tests based on NGS are projected to fuel the next-generation sequencing market growth. Industry of next-generation sequencing is a market that contains infinite companies present in the production of consumables & kits, instruments and advancement of software to foster the NGS market growth in the coming years.

In addition, the usage of the cloud computing in NGS for the management of data in evolving economies are projected to offer opportunities to the manufacturers of next generation sequencing in the coming future. Developments of technology in cloud computing and data integration, demand for clinical diagnostic and increase in demand for scientific research are the factors that are responsible for the growth of global next generation sequencing market.

In addition, growing acceptance of next generation sequencing technology in several end-users and increasing funds in the activities of research & development is boosting the growth of next-generation sequencing market. Moreover, developing applications of NGS in personalized medicine and food testing is anticipated to drive the next generation sequencing market growth in the coming years. Although, scarcity of the skilled professionals are hindering the next generation sequencing market growth.

Browse Complete Next Generation Sequencing (NGS) Market Report @https://www.adroitmarketresearch.com/industry-reports/next-generation-sequencing-market

Legal and ethical discussions are the part of medical research. Journals and funding agencies are submitting the genomic data from the research contributors to the databases are allowing the investigators for controlling the data. The samples and data are sent from databases without the approval of participant by pushing them at risk. Unidirectional flow of data are creating the sense of distrust and exploitation. As a result, ethical and legal issues are hampering the next generation sequencing market growth.

Development of next generation sequencing market is accredited to the significant reduction in the costs of sequencing. For instance, price of sequencing in 2006 was approximately $15 Billion, which ultimately reduced to $6000 Billion in 2014. Several key players like Illumina and Roche have announced the techniques of sequencing which have decreased the cost related to sequencing.

Growing attention of NGS is projected to fuel the usage of precision medicine in oncology on the basis of research setting to the clinical cancer is increasing the growth of global next generation sequencing industry. Market players are involved in studying the novel and existing tests to create the criteria for medical necessity for medical and clinical policies. Global next generation sequencing market trends are developed understanding of the genetic markers of resistance and virulence offered by next generation sequencing is estimated to boost the demand for the technology of diagnosing the infectious disease.

Make an Enquire to Buy This Report @https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/720

Global next generation sequencing market are end-user, application, technology, product & service and region. On considering the end-user, market is divided into biotechnology & pharmaceutical companies, clinics & hospitals, academic institutes and research centers and more. On the basis of application, market is divided into animal & agricultural research, drug discovery, other diagnostic applications, reproductive health diagnostics, infectious disease diagnostics, cancer diagnostics, diagnostics and much more. Based on technology, market is divided into nanopore sequencing, single-molecule real time sequencing, ion semiconductor sequencing, sequencing by synthesis and more. By product & service, market is divided into bioinformatics, sequencing services, services for NGS platforms, NGS platforms, NGS consumables and pre-sequencing products and services. Bioinformatics further subdivided into NGS storage management & cloud computing solutions, NGS data analysis services and NGS data analysis workbenches & software whereas sequencing services are divided into De Novo and Whole genome sequencing, RNA sequencing, Custom Panels and Exome and Targeted Sequencing. NGS platforms are further sub-divided into Oxford Nanopore Technologies, Pacific Biosciences, ThermoFishcer Scientific, Illumina and others. Pre-sequencing products & services market is divided into quality control, target enrichment & library preparation, size selection, A-tailing, End Repair and DNA fragmentation.

Geographically, regions involved in the global next-generation sequencing (NGS) market analysis are Europe, North America, Asia Pacific and Rest of the World. North America holds the largest global next generation sequencing market share followed by Europe. Asia Pacific is expected to rapidly grow in the coming years.

Key players involved in the next generation sequencing market are Agilent Technologies, New England Biolabs, Oxford Nanopore Technolgies Limited, Thermo Fischer Scientific and more.

Key Segments in the Global Next Generation Sequencing Market are-

By End-User, market is segmented into:

By Application, market is segmented into:

By Technology, market is segmented into:

By Product & Service, market is segmented into:

By Regions market is segmented into:

Early Buyers will Get 10% Discount on This Premium Research now @https://www.adroitmarketresearch.com/contacts/discount/720

What to expect from the Global Next Generation Sequencing Market report?

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

About Adroit Market Research:

Adroit Market Research provide quantified B2B research on numerous opportunistic markets, and offer customized research reports, consulting services, and syndicate research reports. We assist our clients to strategize business decisions and attain sustainable growth in their respective domain. Additionally, we support them with their revenue planning, marketing strategies, and assist them to make decisions before the competition so that they remain ahead of the curve.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 (214) 884-6068 / +91 9665341414

See the article here:
Next-Generation Sequencing Market 2020: Product Types and Application, Massive Growth, Demand Insights, Opportunities Assessment and Forecast 2025 -...

Read More...

The Early Edition: March 23, 2020 – Just Security

Wednesday, March 25th, 2020

Signup to receive the Early Edition in your inboxhere.

Before the start of business,Just Securityprovides a curated summary ofup-to-the-minute developments at home and abroad. Heres todays news.

CORONAVIRUS

There were more than 341,000 global cases of thenovel coronavirus as of today and over 14,700 deaths worldwide, according todatafrom Johns Hopkins University. The number of Covid-19 cases in the U.S. has now gone past 35,000, with 417 deaths. CNN reporting.

President Trump announced yesterday that members of the National Guard will be activated to New York, California, and Washington state to help the states fight the coronavirus crisis. The Federal Emergency Management Agency will cover the costs for the deployment to the states, which so far have been hit hardest by the pandemic. Trump approved a disaster declaration for California later last night following previous declarations for New York and Washington state. Allan Smith reports for NBC News.

The presidents move came hours after New York Gov. Andrew Cuomo appealed to Trump to nationalize the effort to acquire masks and other critical protective supplies that are dwindling. I think the federal government should order factories to manufacture masks, gowns, ventilators, the essential medical equipment that is going to make the difference between life and death, Cuomo said during a news conference Sunday in Albany, New York. Its not hard to make a mask or PPE (Personal Protective Equipment) equipment or a gown, but you need companies to do it. Devan Cole and Chandelis Duster report for CNN.

The healthcare system is reaching a breaking point and frontline medical workers are running out of protective equipment, placing them at risk of getting infected. Dr. Melissa Bender and Co-Editor-in-Chief Ryan Goodman report on hospitals policies, including tensions with current guidance from the Centers for Disease Control and Prevention (C.D.C.), at Just Security.

New York is now the epicenter of the U.S. outbreak, accounting for almost half of the countrys confirmed infections and 5% of cases worldwide.In an effort to curb the crisis, Cuomo ordered New York City to crack down on people gathering in public. The governor also announced measures aimed at preparing for a wave of patients, including establishing temporary hospitals in three New York City suburbs and constructing a massive medical bivouac in the Jacob Javits Center on Manhattans West Side. The startling spike is partly the result of increased testing efforts: thousands of tests continued to be carried out, even as officials instructed hospitals to restrict coronavirus testing and save resources for treating patients. Jesse McKinley reports for the New York Times.

The Senate failed to pass a $1.6 trillion emergency coronavirus stimulus bill yesterday after pushback from Democrats who criticized the main elements of the package. Senate Democrats claimed that the measure favored big business over the rights of workers. The bill, which is intended to cushion the economic impact of the new coronavirus and needed 60 votes to advance, was blocked by a split Senate with a 47-47 vote. Marianne Levine and John Bresnahan report for POLITICO.

Speaker Nancy Pelosi (D-Calif.) said the House will introduce its own legislative package after congressional leaders failed to reach an agreement yesterday, adding that she was still hopeful for a bipartisan congressional deal on a coronavirus economic relief bill. Heather Caygle, Sarah Ferris and Marianne Levine report for POLITICO.

The Department of Justice (D.O.J.) has privately asked Congress for the authority to ask chief judges to hold people indefinitely without trial during emergencies part of a drive for new powers amid the pandemic. Documents reviewed by POLITICO lay out the departments requests to lawmakers on an array of topics, including the statute of limitations, asylum and the way court hearings are conducted. Betsy Woodruff Swan reports for POLITICO.

The intelligence community was warning of the global danger posed by the new coronavirus throughout January and February as the White House minimized the threat and was slow to roll out nationwide measures, according to U.S. officials familiar with spy agency reporting. The reports did not clarify when the virus might spread in the U.S. or recommend specific steps to mitigate it, but they did track the international spread of the coronavirus and warn that China was initially playing down the seriousness of the outbreak. Shane Harris, Greg Miller, Josh Dawsey and Ellen Nakashima report for the Washington Post.

A Defense Department contractor has died from coronavirus, the first military-related fatality from the illness. The Virginia-based contractor, who worked inside the Defense Security Cooperation Agency (D.S.C.A.), died on Saturday, the Pentagon said in a statement yesterday. Ellen Mitchell reports for the Hill.

Rand Paul (R-Ky.) hasbecome the first U.S. senatorto test positive for Covid-19. Natalie Andrews and Lindsay Wise report for the Wall Street Journal.

The D.O.J. announced yesterday that it was taking measures to close down a website falsely claiming to have access to vaccine kits supposedly made by the World Health Organization (W.H.O.) to prevent coronavirus. In a press release, Justice Department officials accused the unidentified operators of coronavirusmedicalkit.com of engaging in a wire fraud scheme seeking to profit from the confusion and widespread fear surrounding COVID-19. John Bowden reports for the Hill.

Four U.S. senators are under scrutiny over allegations they used insider knowledge about the impending coronavirus crisis to sell shares before the virus-induced market meltdown. Republicans Richard Burr (N.C.) and Kelly Loeffler (Ga.) face calls to leave office after dumping millions of stocks last month. The BBC reporting.

A government watchdog is evaluating the Department of Health and Human Services (H.S.S.) response to the coronavirus outbreak and appraising nursing home preparedness after a number of elderly residents became poorly and died, a spokesperson for the H.H.S. inspector general said. Priscilla Alvarez reports for CNN.

Irans Supreme Leader has rejected Americas offer of aid to help the country with its battle against coronavirus. In a televised speech, Ayatollah Ali Khamenei hinted at a conspiracy theory, also voiced by some Chinese officials, that America was responsible for the pandemic. I do not know how real this accusation is but when it exists, who in their right mind would trust you to bring them medication? Khamenei said. Possibly your medicine is a way to spread the virus more. Without offering any evidence, he also alleged that the virus is specifically built for Iran using the genetic data of Iranians which they have obtained through different means. Al Jazeera reporting.

The U.S.-led military coalition in Iraq is pulling out some troops partly due to the coronavirus pandemic, the coalition confirmed Friday. The coalition is adjusting our positioning in Iraq for two reasons: long-planned adjustments to reflect success in the campaign against Daesh; and short-term moves to protect the force during the coronavirus pandemic, the coalition said in a statement, using a substitute name for the Islamic State group (ISIS). Looking ahead, we anticipate the coalition supporting the Iraqi Security Forces from fewer bases with fewer people, it added. Rebecca Kheel reports for the Hill.

Trump sent a letter to North Korean leader Kim Jong-un seeking to maintain good relations and offering help in the countrys fight against the coronavirus, Kims sister said yesterday, but she warned it was not enough to boost relations. A senior Trump administration official confirmed Trump sent a letter to the North Korean leader, saying that the move was consistent with his efforts to engage global leaders during the ongoing pandemic. Min Too Kim reports for the Washington Post.

Health officials in Syria have announced the first coronavirus infection in the country after weeks of rejecting opposition claims that the disease had already reached a nation with a wrecked healthcare system and thousands of Iranian-backed militias and Shiite pilgrims. The arrival of the global pandemic in Syria in addition to the Gaza Strip has sparked fears it could spread rapidly in some of the most vulnerable areas in the Middle East. Reuters reporting.

German Chancellor Angela Merkel said she was self-quarantining after coming into contact with a doctor who has the virus. Her government also banned gatherings of more than two people, excluding families. Katrin Bennhold and Melissa Eddy report for the New York Times.

Secretary of State Mike Pompeo on Friday accused China, Russia and Iran of spreading disinformation about the coronavirus pandemic, in what is a supposed effort to plant fear and confusion. Speaking at the White House, Pompeo described the disinformation campaigns as being pretty diffused, saying that the government has observed individuals, as well as the three foreign foes, circulate false information online. There are coordinated efforts to disparage what America is doing and our activity to do all the things President Trump has set into motion, the secretary said during a press briefing on the coronavirus. Olivia Beavers reports for the Hill.

Members of Congress should be allowed to vote remotely during the coronavirus emergency, Justin Ling argues at Foreign Policy, citing a powerful letter from three elective representatives urging House leadership to change the rules.

A compelling case for action to be taken through the Defense Production Act is made out by former Chief Judge of the Court of Appeals for the Armed Forces and National Security Council (N.S.C.) Legal Adviser James E. Baker at Just Security.

A look at what the Act would allow for and why Trump is reluctant to wield his federal powers is provided by Amber Phillips at the Washington Post.

A map and analysis of all confirmed cases of the virus in the U.S. is available at the New York Times.

U.S. and worldwide maps tracking the spread of the pandemic are available at theWashington Post.

A list of the measures taken by other countries to contain the spread of the new coronavirusis compiledby Al Jazeera.

Latest updates on the pandemicatThe GuardianandNBC News.

AFGHANISTAN

Secretary of State Mike Pompeo landed in Kabul today on an unannounced visit to help bridge a political impasse that has undermined a U.S. peace deal with the Taliban, struck at the end of February. Pompeo is expected to meet separately with Afghan President Ashraf Ghani and his chief political opponent, Abdullah Abdullah, who is attempting to set up a parallel government, before the two Afghan rivals are due to come together for a one-on-one meeting. AP reporting.

Afghan government officials met by videoconference yesterday with Taliban delegates to discuss a prisoner exchange that is a part of a broader push for peace, the U.S. special envoy for Afghanistan, Zalmay Khalilzad, said in a message sent Twitter, offering some prospect of a breakthrough on a matter that has paralyzed the two sides and threatened a budding peace process. The two sides deliberated for over two hours in a Skype meeting facilitated by the United States and Qatar, officials said. Reuters reporting.

IRAN

The White House apparently is divided over whether to escalate military action against Iran, with Secretary of State Mike Pompeo and national security adviser Robert C. OBrien calling for a strong response to rocket attacks that had killed two American soldiers at a base north of Baghdad, and Defense Secretary Mark Esper and Gen. Mark A. Milley, the chairman of the Joint Chiefs of Staff, arguing that the Pentagon and intelligence agencies lacked clear evidence that the attacks, launched by the Shiite militia group Khataib Hezbollah, had been directed by the Islamic Republic. The New York Times reporting.

The Trump administration yesterday condemned France for releasing an Iranian man wanted for prosecution by the United States in an apparent prisoner swap with Iran. The State Department said it deeply regrets the unilateral French move to free Jalal Rohollahnejad, who was the subject of a U.S. extradition request on charges of breaching American sanctions on Iran. Spokesperson Morgan Ortagus said in a statement that France had failed to uphold its commitments under a joint extradition treaty and harmed the cause of justice. AP reporting.

ISRAEL-PALESTINE

Israeli Prime Minister Benjamin Netanyahu Saturday offered to step down next year as part of a proposed power-sharing accord with his chief rival meant to guide the country through the coronavirus crisis and end a year-long political standoff. Netanyahu made his proposal during a nationally televised interview, calling for the creation of a three-year emergency unity government with the rival Blue and White Party. Netanyahu told Channel 12 TV that he would stay as prime minister for the first 18 months, and allow opposition leader Benny Gantz to assume the post for a second year-and-a-half term in September 2021. He said each party would have an identical number of seats in the Cabinet. AP reporting.

Netanyahus political opponents yesterday asked Israels Supreme Court to block what they described as a power grab by the caretaker government under the pretense of tackling the coronavirus epidemic. The petitioners asked the court to force parliament to resume its full activities, despite restrictions imposed by Parliament Speaker Yuli Edelstein, a member of Netanyahus ruling Likud party, because of public health concerns, citing a threat to Israeli democracy. Isabel Kershner reports for the New York Times.

OTHER DEVELOPMENTS

Lora Shiao, a career U.S. intelligence officer, has been tapped as the next acting director of the National Counterterrorism Center, the governments principal clearinghouse for intelligence on terrorist threats, Trump administration officials said. The New York Times reporting.

The United States carried out a successful test on an unarmed prototype of a hypersonic missile, a nuclear-capable weapon that could speed up the arms race between superpowers. The Pentagon on Friday said a test glide vehicle traveled at hypersonic speeds more than five times the speed of sound, or Mach 5 to a designated impact point. AFP reporting.

North Korea on Saturday test-fired two presumed short-range ballistic missiles into the sea, South Koreas military said, as it continues to expand military capabilities following two months of relative silence. Al Jazeera reporting.

An excerpt from the untold story of Saudi Arabias Crown Prince Mohammed bin Salman and his unchecked rise to power, written by the Beirut bureau chief for The New York Times, is available at The Times.

A look at what is driving the political resistance to repatriating the thousands of foreign fighters who fought on behalf of ISIS in Syria and what might be done to curb such resistance is provided by Dan E. Stigall at Just Security.

The rest is here:
The Early Edition: March 23, 2020 - Just Security

Read More...

Discover: What is the link between cannabis and psychosis? – Sudbury.com

Wednesday, March 25th, 2020

The dose makes the poison.

Thats a shortened version of a quote by Paracelsus (1493-1541), a doctor often referred to as a Father of toxicology the study of the nature, effects, and detection of poisons. His teachings are that every medicine is a poison, and every poison, a medicine: it all comes down to dose.

With traditional medicines, dose is decided by research on the effects of certain substances, both on the general population, and the individual to be treated.

But cannabis has put a strain on this notion. While the number of studies is increasing, there isnt enough research yet to fully understand its effects, even as patients successfully add cannabis to their treatment plans. But some are under the misconception that cannabis is safe and natural; unfortunately, cannabis can come with a downside.

For instance, you may have heard of an incident in 2018, a man accused of the murder and beheading of his father. Though he voluntarily pled guilty to the charge of murder, the plaintiff in the case added to the record his defense: cannabis-induced psychosis.

While this is a controversial opinion because it assumes a one-time induction of a psychotic state that spurred the event, rather than cannabis causing the onset of chronic issues, there is a need for concern around cannabis use, especially when it is not from a recognized source or when the dose isnt properly considered.

Psychosis and cannabis

Psychosis and cannabis have been linked for some time more than a century, in fact. Psychosis is described as a disturbance in brain functioning that results in the sufferer feeling unsure as to what is real, and what is not. It can cause thought disorders, hallucinations both visual and auditory and delusions. Schizophrenia is, in its simplest description, chronic psychosis.

Cannabis is considered connected to schizophrenia by Health Canada, and in their cannabis Resource Series, they point to several risk factors, like the age of the person upon first use is important, especially if they are under 16.

As well, they state cannabis consumption by those with a family history of psychosis mean they are 2.5 to 10 times more likely to develop schizophrenia than non-users with the same family history. Also an issue is the frequency of use, and incorrect dosing using too much of a high potency strain.

But while they are sure about some aspects, it is clear that there is much more research to be done. Even Health Canada is specific that while there is strong evidence that cannabis will increase your risk: The exact underlying mechanism is still largely unknown

In June of 2019, Ian Hamilton, a specialist in Health Sciences from the University of York (UK) and Mark Monaghan, specialist in Social Policy at the University of Birmingham (UK) wrote an paper summarizing what has been understood so far, and what holes are left within the research surrounding cannabis and Psychosis specifically Schizophrenia.

Current thinking

They described three hypotheses that are re-occurring in research. The first is direct, cannabis causes schizophrenia; that it would trigger the illness in someone who would not have developed it had they not been exposed to cannabis. The second is that individuals with a pre-disposition to schizophrenia use cannabis to mitigate its early symptoms, and that is why there is link.

A third suggests that one might have childhood trauma that could trigger schizophrenia in itself, then paired with the desire to medicate the effects of the trauma with intoxicants. They are not connected, but could be seen that way.

The issues with proving these hypotheses come in the measurement of data, done mostly through observation and subjective assessment.

Gaps in the current research include gender - as in many medical research studies, the sample groups are mostly male and that the studies focus on western-world usage, skewing the data based on cultural influences.

There's also the role of tobacco. Currently, tobacco is also appearing as an independent risk factor for psychosis, and cannabis and tobacco are often used in combination.

In 2016, an estimated 192 million people worldwide used cannabis, and thats before Canadian legalization; but that only brings cannabis to third in popularity, behind alcohol and tobacco. There is a need for cannabis and tobacco to be uncoupled for further study.

However, there is an ever-increasing number of conditions treated with cannabis, and because of this, there are many people looking for help without understanding the risk.

Cannabis as medicine

Sudbury physician Dr. Lionel Marks De Chabris has been prescribing cannabis to his patients since 2007, and though there are risks associated with cannabis as medicine, he notes that the risks of other medicines specifically pain medicines like opiates could be quite higher, while also less effective.

He has read the research available and says, in his belief, cannabis doesnt cause schizophrenia, but if you have a genetic risk for having schizophrenia i.e. you may well develop it at some point in your life and if you use cannabis, you can trigger that at an earlier age. Thats not trivial; Schizophrenia is a terrible, life-altering disease.

He is careful to screen his patients for any personal or family history of psychosis, mental illness, and schizophrenia, and will advise those patients to refrain from cannabis completely. For others, he explains how to safely consume it.

Understanding dose

Because most recreational consumers are looking for the high, many are looking to find the highest THC (the hallucinogenic compound, Tetrahydrocannabinol) possible, and then consuming extremely excessive amounts. Marks De Chabris points to this when it comes to issues of psychosis: its not the potency of the strain, it is the amount consumed that will hurt you.

He compares it to alcohol. You wouldnt consider beer to be better for you than wine because of its lower alcohol content, you would change the amount you consumed. Its like when you ask for a glass of whiskey, you dont ask for a pint. You ask for a single ounce.

But dosing becomes difficult when the drug supply is from disreputable sources. Ive spoken to patients who tried particularly some of the edibles that are currently illegally available that have huge amounts of THC in them, he said. Ive seen edibles online that 150mg of THC in one little gummy the starting dose for a nave user is 10. So, one gummy has fifteen doses.

Take one candy, and you could be in real trouble.

What you need to know

Thankfully, Marks de Chabris says most of them time the answer to over consumption discomfort and other unwanted side effects of cannabis is to simply go to sleep. He also notes: If youre feeling anxious, if youre feeling paranoid and you understand that the reason for that is youve taken too much THC, just that knowledge can help to offset some of the fear around that excessive dosing.

Of course, if you believe something much worse is happening, getting medical attention is your best chance, and one without risk now that cannabis is legal. If its really bad then going to an emergency department and getting some medication to help sedate you is reasonable, but that would be very rare.

But he also notes the steady rise is consumption, and the lack of corresponding rise in psychosis.

We know that the use of cannabis in the western world has gone up, I think the last study I saw was 700 per cent over the last 20 years, so thats a huge increase in the use of cannabis, he said.

Over that same period, the rate of schizophrenia has not changed in fact it may have gone down a little. So, if cannabis was causing Schizophrenia, where are all the patients with schizophrenia?

As for his safe consumption recommendations: Start low and go slow. Aim for low THC with at least some Cannabidiol (CBD) to mitigate any unwanted effects, and wait, as it takes a 30 minutes to feel the effects of smoking, and up to two hours for ingestion.

And while the research is ever-increasing, currently, safe consumption seems to come down to this: know your source, know yourself, buy informed and buy legally. After all, you wouldnt buy moonshine from your neighbours bathtub without at least thinking deeply about your life choices.

Jenny Lamothe is a freelance writer, proof-reader and editor in Greater Sudbury. Contact her through her website,JennyLamothe.com.

Read more from the original source:
Discover: What is the link between cannabis and psychosis? - Sudbury.com

Read More...

Medical Ethics Society Conference Explores the Intersection of Patient Autonomy and Jewish Law – Yu News

Sunday, March 22nd, 2020

On Sunday, Feb. 23, 2020, over 250 people attended the 13th Annual Medical Ethics Society (MES) Conference presented by the YU Student Medical Ethics Society and the Center for the Jewish Future (CJF). Who Shall Live and Who Shall Die? examined Jewish perspectives on patient autonomy and decision-making in modern medicine.

The conference opened with remarks by the co-presidents of MES, Bailey Frohlich 20S and Tzvi Cantor 21YC, who welcomed the audience. Rabbi Yaakov Glasser 99YC, 01R, 05A, the David Mitzner Dean of CJF, addressed the audience and was followed by the conference chairman, Rabbi Dr. Edward Reichman 86YC, 90E, 97R, who introduced the honoree of the conference, Rabbi Dr. Moshe D. Tendler 48R, the Rabbi Isaac and Bella Tendler Professor of Jewish Medical Ethics, a professor of biology at YU and a rosh yeshiva at the Rabbi Isaac Elchanan Theological Seminary (RIETS). The conference, sponsored by the Community Synagogue of Monsey, was in honor of Rabbi Tendler, who spoke about risk and patient autonomy in Talmudic law.

The first panel featured Dr. Richard Grazi, director of the Division of Reproductive Endocrinology at Maimonides Medical Center and Founder of GENESIS, and Rabbi Dr. Richard Weiss 83YC, 96R, adjunct instructor in biology at Stern College for Women and rabbi of the Young Israel of Hillcrest. Their panel was titled Patient Autonomy Versus Physician Autonomy In Assisted Reproductive Technology and addressed questions such as how an Orthodox physician can navigate his or her patients request to perform elective Preimplantation Genetic Diagnosis (PGD) for sex determination, or what to do when a single woman asks for donor insemination.

Dr. Grazi spoke about various case studies he has seen in his practice in which the patients wishes conflicted with his own religious beliefs. Both he and Dr. Weiss then evaluated each case and discussed the halachic [Jewish legal] issues that arise in similar situations as well as possible clinical approaches to resolving the ethical issues of autonomy faced by physicians. After the panel concluded, a comment by a member of the audience mirrored the feeling of many when he stated, The miracle of birth is a miracle of birth, no matter how it is achieved.

The second session, titled Physician Assisted Suicide (PAS): Ethics, Legality and Halakha, featured Dr. Susan Cohen, medical director of palliative care at Bellevue Hospital and associate professor of the Department of Medicine at NYU-Langone; Assemblyman Gary Schaer, deputy speaker in the New Jersey State Assembly and vice-chair of the Appropriations Committee; and Rabbi Daniel Z. Feldman 96YC, 98R, rosh yeshiva at RIETS.

Dr. Cohen discussed the medical ethics of PAS and the physician-patient interaction during end-of-life care. Assemblyman Schaer then presented the legal arguments that arose for and against the Aid in Dying for the Terminally Ill Act passed by the New Jersey State Legislature in August 2019. He spoke movingly about his personal experience with regards to his father and the issues and challenges he faced in his voting decision. Rounding out the discussion was Rabbi Feldman, who explored the halachic aspects of PAS, end-of-life situations and balancing compassion with Jewish law.

The third and final session discussed Navigating Cases of Diminished Capacity with Dementia and Alzheimers Patients and featured Dr. Hannah Lipman, director of Bioethics at Hackensack University Medical Center and associate professor at Hackensack Meridian School of Medicine at Seton Hall University; and Rabbi Mordechai Willig 68YC, 71R, the Rabbi Dr. Sol Roth Professor of Talmud and Contemporary Halakhah, rosh yeshiva at the Yeshiva Program/Mazer School of Talmudic Studies, rosh kollel at RIETS, and spiritual leader of the Young Israel of Riverdale.

Dr. Lipman discussed the challenges involved in dealing with patients who have dementia, such as who makes medical decisions for the patient when the patient is no longer capable of making such decisions for himself or herself, whether the patients wishes in their current state of limited capacity conflict with their own past wishes, and how a physician can facilitate shared decision-making between elderly patients and various family members who have conflicting opinions. Following Dr. Lipmans presentation, Rabbi Willig discussed the halakhic questions that arise when dealing with patients and family members who have dementia and cannot entirely express their own opinions.

The yearly conference is considered highly relevant for members of the Jewish community, since many of the issues explored are compounded by halachic considerations that require the guidance of rabbinic authority.

As Rabbi Tendler introduced the theme of Jewish law and autonomy, I looked out at our captivated audience of over 250 students, physicians and community members and realized that our countless hours of hard work paid off, said Frohlich. Based on our attendance, robust Q&A sessions with the speakers and the overwhelmingly positive feedback we received, I felt that we successfully generated a positive and productive conversation about these increasingly sensitive and nuanced medical ethics issues, thus achieving the mission of the YU Medical Ethics Society. She added, By bringing in leading physicians, rabbis, ethicists, lawmakers and scientists who are experts in their respective fields, MES looks forward to presenting future informative and thought-provoking conferences in order to provide YU students and surrounding community members with a deeper insight into how to navigate complex medical ethics topics.

Read more:
Medical Ethics Society Conference Explores the Intersection of Patient Autonomy and Jewish Law - Yu News

Read More...

3D-printed medical valves are helping the COVID-19 outbreak in Italy – The American Genius

Sunday, March 22nd, 2020

Artificial intelligence (AI) has revolutionized business practices across many industries. With 39% of health care providers investing in AI-related technologies, its safe to say its about to transform the medical industry as well. AIs disruptive potential may increase profits in other sectors, but in health care, it can save lives.

While robots arent quite ready to replace doctors, they can help them accomplish their tasks with higher speed and precision. AI in the hospital is not just a thing of the future, either. All around the world, smart machines are already assisting medical staff in a variety of ways.

As this technology refines, machine learning will become an increasingly regular part of medicine. Here are seven ways AI will transform health care in the coming years.

1. Robot-Assisted Surgery

It may sound like something out of a sci-fi movie, but surgery robots are already in use. In 2017, more than 690,000 surgeries were assisted by robots in the U.S. alone. As these machines continue to demonstrate their worth, theyll appear in more operating rooms.

Robotic surgeons like the da Vinci Surgical System offer more precise and less invasive movements than human hands and traditional tools. With AI, they can improve upon surgical methods. AI-enabled surgery bots can notice reactions in a patient invisible to the human eye and make necessary adjustments.

2. Early Diagnoses

Intelligent programs can quickly analyze vast amounts of information. This unique talent makes AI ideal for making preliminary diagnoses in patients. Smart machines can take note of patients symptoms and interpret them to make an early diagnosis while doctors make their rounds.

The accuracy of these diagnoses will improve as AI develops, but even at its current state, they can be useful. Doctors can use them as a starting-off point. A list of likely diagnoses can be a helpful resource to doctors when trying to diagnose patients as quickly as possible. They might also make health care professionals consider options they otherwise wouldnt have thought of, increasing accuracy.

3. Administrative Assistance

Treating patients is not the only duty of health care professionals. Doctors and nurses have to take records of patient data, from symptoms to insurance information, so they can refer to them later or send them to other hospitals. This process can take time, and any issues along the way can create problems for patients and doctors alike.

IT usability is a critical part of health care, and AI can optimize it. Intelligent systems can find ways to streamline the information-sharing process, ensuring health workers get the data they need as soon as possible. AI can also handle administrative tasks like scheduling and logistics, allowing hospital staff to focus on more pressing concerns.

4. Health Screenings

Just as AI applications can diagnose patients, they can also make predictions about a persons fitness for a given situation. Predictive analytics is an AI function that analyzes historical data to make predictions about future outcomes. AI systems can use predictive analytics to perform more nuanced health screenings.

AI can tell doctors is a patient would be fit for surgery or not. Similarly, it can advise people if they arent a suitable candidate for physically exerting activities or tests. These analytics consider a wide range of data, including things a human might overlook, leading to more accurate predictions.

5. Remote Monitoring

AI can also optimize health care outside of the hospital. Wearable technology is already prevalent with products like Fitbit, and the medical industry can use this to its advantage. With wearable health-monitoring devices, doctors can monitor their patients remotely.

Remote monitoring devices can alert patients if they need to see a doctor. Should an emergency occur, they can also alert hospital staff so they can send an ambulance. These noninvasive technologies will allow patients with conditions such as heart disease to live without fear by providing them with almost instant assistance.

6. Robot Nurses

Intelligent robots can help fix the nursing labor shortage by filling in those vital roles. Nursing robots are already working in Japanese hospitals and may soon see use in the U.S. These machines can help patients move, reduce their stress and remind them to take their medicine.

With AI, these robot nurses can adapt to each patients needs and desires. By analyzing how different people respond to various stimuli and situations, they can customize care. Intelligent nurse robots treat patients in a manner ideal for their health and comfort needs.

7. AI-Enabled Genomics

Compared to humans, AI is better suited for data-heavy tasks. Since DNA sequencing is a form of data analysis, its an ideal area to employ AI.

Using artificial intelligence in genomics has already shown impressive results. In 2019, an AI system identified new genetic mutations that contributed to autism. The system could detect patterns in DNA humans would not be able to, as well as predict how changing each gene would affect a person.

AI Is Revolutionizing Medicine

Artificial intelligence is changing the way the health care industry operates. With continued research and improvement, AI systems could save countless lives.

Read the rest here:
3D-printed medical valves are helping the COVID-19 outbreak in Italy - The American Genius

Read More...

Uncharted territory: Legal experts weigh in on the COVID-19 outbreak – Harvard Law School News

Sunday, March 22nd, 2020

1000s of individuals in the USA have examined optimistic for COVID-19, and the dying toll around the globe has surpassed 6,000. Italy is below lockdown and in New York Metropolis the federal government is demanding companies together with bars, eating places and film theaters be closed in an effort to stem the unfold of the virus. After draconian measures have been applied in China to halt the fast an infection charge of the virus, together with motion restrictions, massive scale surveillance and compelled isolation, it appears such measures are working, with new instances in China decliningBeneath laws from the Occupational Security and Well being Administration plus legal guidelines together with the People with Disabilities Act (ADA), HIPAA, and the Genetic Info Nondiscrimination Act (GINA), amongst others, employers should respect employees privateness and different rights. With coronavirus, that will preclude administering any form of well being testing or straight inquiring about an workers well being situation or medical prognosis, says Elizabeth M. Renieris, a lawyer and a fellow at Harvard Colleges Berkman Klein Center for Web and Society This isnt a time for employers to opportunistically accumulate further details about their staff or to introduce worker surveillance measures, says Renieris. Staff dont give up all of their privateness rights in a disaster.

Read more:
Uncharted territory: Legal experts weigh in on the COVID-19 outbreak - Harvard Law School News

Read More...

European Medicines Agency taking action to accelerate development of medical products to treat and coronavirus – The Parliament Magazine

Friday, March 6th, 2020

Photocredit: Press Association

Guido Rasi, the European Medicines Agency's executive director, said the EMA has activated its plan for managing emerging health threats.

Rasi added, "The new coronavirus has been declared a public health emergency of international concern by the World Health Organization, and we are drawing on the strong expertise of the European medicines network to provide fast-track scientific advice and give prompt feedback on any proposed medicine developments.

The EMA, now based in Amsterdam, says it is collaborating and exchanging information with EU public health authorities and the commission.

RELATED CONTENT

An agency spokesman said, There are currently no commercially available medicinal products that are authorised to detect, treat or prevent infections with the virus. The EMA is ready to support medicine developers with all available regulatory tools to advance and expedite the development of effective measures to fight and prevent the spread of this virus.

This is a new strain of coronavirus that has not been previously seen in humans. Although the most likely primary source of this outbreak is of animal origin, human-to-human transmission has been confirmed and investigations are ongoing to determine all sources. Cases have now been detected in several countries in Asia, Australia, Europe and North America.

Further global spread is likely.

Reports of medicines shortages are increasingly prevalent in Europe, warned, Christoph Stoller, President of Medicines for Europe, which represents the generic, biosimilar and value-added medicines industries across Europe.

He said, Ensuring the availability of essential medicines should be an EU priority. The EU should tackle the economic and regulatory root causes of shortages and establish a pan-European mechanism to coordinate EU and national policies to reduce the risk of shortages and to avoid spill over effects through which one countrys policy would create supply issues in another.

"There are currently no commercially available medicinal products that are authorised to detect, treat or prevent infections with the virus. The EMA is ready to support medicine developers with all available regulatory tools to advance and expedite the development of effective measures to fight and prevent the spread of this virus"European Medicines Agencyspokesman

He added, Preventing supply issues becomes especially pertinent considering the ongoing COVID-19 coronavirus outbreak globally.

Meanwhile, the EMA, which was based in London but had to relocate because of Brexit, has insisted there is no risk to the supply of medicines due to the UKs EU exit during the transition period.

In a bid to allay fears that the supply of medicines could be adversely affected, the agency has reassured consumers and businesses alike but also warned of legal repercussions when the transition period ends.

An EMA spokesman said that during the transition period until December 31 2020, EU pharmaceutical law will continue to apply to the UK meaning that until the end of the transition period pharmaceutical companies can continue to carry out activities in the UK and supply their medicines as before.

Continue reading here:
European Medicines Agency taking action to accelerate development of medical products to treat and coronavirus - The Parliament Magazine

Read More...

Stalked by the Fear That Dementia Is Stalking You – The New York Times

Sunday, February 23rd, 2020

One of her sisters was tested for the APOE4 genetic variant; results were negative. This is no guarantee of a dementia-free future, however, since hundreds of genes are implicated in Alzheimers, Lewy body dementia, frontotemporal dementia and vascular dementia.

Rather than get genetic or neuropsychological tests, Ms. Super has focused on learning as much as she can about how to protect her brain. At the top of the list: managing her depression as well as stress. Both have been linked to dementia.

Also, Ms. Super exercises routinely and eats what is known as a MIND-style diet, rich in vegetables, berries, whole grains, nuts, fish and beans. She is learning French (a form of cognitive stimulation), meditates regularly and is socially and intellectually active.

According to a growing body of research, physical inactivity, hearing loss, depression, obesity, hypertension, smoking, social isolation, diabetes and low education levels raise the risk of dementia. All of these factors are modifiable.

What if Ms. Super started having memory problems? I fear I would get really depressed, she admitted. Alzheimers is such a horrible disease: To see what people you love go through, especially in the early stages, when theyre aware of whats happening but cant do anything about it, is excruciating. Im not sure I want to go through that.

Dr. Gefen of Northwestern said she tells patients that if cognitive testing is something thats going to stress you out, then dont do it.

Nigel Smith, 49, had a change of heart after caring for his mother, Nancy Smith, 81, whos in hospice care in the Boston area with Alzheimers. When he brought his mother in for a neuropsychological exam in early 2017 and she received a diagnosis of moderate Alzheimers, she was furious. At that point, his mother was still living in the familys large home in Brookline, Mass., which she refused to leave.

See the original post here:
Stalked by the Fear That Dementia Is Stalking You - The New York Times

Read More...

On #WorldPangolinDay, we celebrate this roly-poly scaly anteater, one of the world’s most trafficked mammals – Massive Science

Tuesday, February 18th, 2020

The 2019 novel coronavirus (2019-nCoV) outbreak has sparked a speedy response, with scientists, physicians, and front-line healthcare professionals analyzing data in real-time in order to share findings and call out misinformation. Today, The Lancet published two new peer-reviewed studies: one which found that the new coronavirus is genetically distinct from human SARS and MERS, related viruses which caused their own outbreaks, and a second which reports clinical observations of 99 individuals with 2019-nCoV.

The first cases of the coronavirus outbreak were reported in late December 2019. In this new study, Nanshan Chen and colleagues analyzed available clinical, demographic, and laboratory data for 99 confirmed coronavirus cases at the Wuhan Jinyintan Hospital between Jan 1 to Jan 20, 2020, with clinical outcomes followed until 25th January.

Chen and colleagues reported that the average age of the 99 individuals with 2019-nCoV is around 55.5 years, where 51 have additional chronic conditions, including cardiovascular and cerebrovascular (blood flow to the brain) diseases. Clinical features of the 2019-nCoV include a fever, cough, shortness of breath, headaches, and a sore throat. 17 individuals went on to develop acute respiratory distress syndrome, resulting in death by multiple organ failure in 11 individuals. However, it is important to note here that most of the 2019-nCoV cases were treated with antivirals (75 individuals), antibiotics (70) and oxygen therapy (75), with promising prognoses, where 31 individuals were discharged as of 25th January.

Based on this sample, the study suggests that the 2019 coronavirus is more likely to affect older men already living with chronic conditions but as this study only includes 99 individuals with confirmed cases, it may not present a complete picture of the outbreak. As of right now, there are over 6,000 confirmed coronavirus cases reported, where a total of 126 individuals have recovered, and 133 have died.

In a second Lancet study, Roujian Lu and their fellow colleagues carried out DNA sequencing on samples, obtained from either a throat swab or bronchoalveolar lavage fluids, from eight individuals who had visited the Huanan seafood market in Wuhan, China, and one individual who stayed in a hotel near the market. Upon sequencing the coronaviruss genome, the researchers carried out phylogenetic analysis to narrow down the viruss likely evolutionary origin, and homology modelling to explore the virus receptor-binding properties.

Lu and their fellow colleagues found that the 2019-nCoV genome sequences obtained from the nine patients were very similar (>99.98% similarity). Upon comparing the genome to other coronaviruses (like SARS), the researchers found that the 2019-nCoV is more closely related (~87% similarity) to two bat-derived SARS-like coronaviruses, but does not have as high genetic similarity to known human-infecting coronaviruses, including the SARS-CoV (~79%) orMiddle Eastern Respiratory Syndrome (MERS) CoV (~50%).

The study also found that the 2019-nCoV has a similar receptor-binding structure like that of SARS-CoV, though there are small differences in certain areas. This suggests that like the SARS-CoV, the 2019-nCoV may use the same receptor (called ACE2) to enter cells, though confirmation is still needed.

Finally, phylogenetic analysis found that the 2019-nCoV belongs to the Betacoronavirus family the same category that bat-derived coronaviruses fall into suggesting that bats may indeed be the 2019-nCoV reservoir. However, the researchers note that most bat species are hibernating in late December, and that no bats were being sold at the Huanan seafood market, suggesting that while bats may be the initial host, there may have been a secondary animal species which transmitted the 2019-nCoV between bats and humans.

Its clear that we can expect new findings from the research community in the coming days as scientists attempt to narrow down the source of the 2019-nCoV.

More here:
On #WorldPangolinDay, we celebrate this roly-poly scaly anteater, one of the world's most trafficked mammals - Massive Science

Read More...

Germany Joins the Genomes Initiative – Lexology

Saturday, February 8th, 2020

In January, Germany joined the EU's "1+ Million Genomes Initiative". While the German government had previously declined to actively participate in the project and Germany had merely assumed the role of an observer, it can now become involved in sharing genome data across Europe for research purposes. Genome analysis is not only instrumental to the future diagnosis, prevention and treatment of rare diseases, it is also an important economic factor in digital health.

1. GENOME SEQUENCING

Human genomes are made up of at least 20,000 genes containing all our genetic information. Genome sequencing allows us to decode almost all mutations in human genomes. This enables us to identify individual gene defects causing diseases and thus to better diagnose and treat rare diseases. Increasingly, whole genome sequencing is being used in the field of tumours to identify mutations and tailor medication to the genetic makeup of a specific tumour.

But although the development of new technologies such as high throughput DNA sequencing over recent years has made it much easier and faster to carry out human genome research, the mutations that cause disease have been determined only for around 4,000 of the 20,000 protein-coding human genes. Medical researchers will probably need decades to identify all genetic causes of disease.

2. THE EU'S GENOME INITIATIVE: 1 MILLION GENOMES BY 2022

In order to produce reliable scientific findings, researchers need broad access to genomic data from both healthy and sick patients. The aim of the EU's Genome Initiative is to collect at least one million sets of genomic data by 2022 and make these accessible beyond EU borders. The initiative is part of the EU's agenda for the digital transformation of health and care, which is aimed at harnessing the potential of new digital technologies to improve healthcare. In a declaration published in April 2018, EU, EEA and EFTA countries agreed to work together to build up and link genome databases to form a suitable technical infrastructure. So far, 21 EU member states and Norway have signed the declaration. Ten specialised working groups have been set up to look into ethical, legal and social issues, common data standards, best practices for sequencing, issues relating to health economics, research and public sector participation, as well as to analyse uses for rare diseases, cancer and common complex diseases.

3. CURRENT LEGAL SITUATION IN GERMANY

The current market leaders in genome analysis are the USA, China, the UK and some EU member states from Continental Europe. While other countries have already introduced whole genome sequencing as a standard procedure in genetic diagnostics and have produced millions of sets of data, Germany has only generated tens of thousands of data sets from whole genome sequencing. This cautious approach was put down to the particularly high level of interoperability required and restrictions due to data protection regulations.

There are certainly still some legal and also financial obstacles to be overcome in Germany. Although the German Genetic Diagnostics Act (Gendiagnostikgesetz, "GDA") provides a legal framework for genome sequencing for medical purposes and establishing parenthood, there is no specific legislation governing genome analysis for research purposes.

Genetic Diagnostics Act on genome analysis for medical purposes and establishing parenthood

Genome analysis for medical purposes entails diagnostic and predicative genetic testing. Like genome analysis to establish parenthood, it is governed by the GDA. It stipulates that doctors have to provide genetic advice, restricts genome testing and analysis to doctors with appropriate training and provides for a patient's right "not to know" the results. Moreover, according to the GDA, patients must be given comprehensive information on the procedure beforehand and they must grant their consent.

Genome sequencing has already become part of standard care in Germany and since mid-2016 has been included in the German physicians' fee schedule. However, unlike in England, the German system does not cover sequencing of whole genomes but only of a very small gene panel of up to 25 kilobases, which corresponds to an average of four genes. For some diseases, up to 1,000 genes need to be analysed. Doctors wishing to perform larger sequencing projects have to apply for extra-budgetary services. Since such applications have often been rejected in the past due to the strict requirements, there is currently no incentive for physicians to perform medical genome analysis.

Pursuant to the GDA, genetic testing to establish parenthood requires the consent of the individuals providing the samples and can also be performed by specialists not qualified as doctors, for instance molecular biologists. Unlike in the USA, for example, analyses performed privately are not permissible.

No specific legislation on genome analysis for research purposes

The German legislator deliberately decided not to extend the scope of the GDA to cover genome analysis for research purposes, including general research on the factors affecting human characteristics. By contrast to predictive genetic testing, such research is not aimed at developing specific treatment for specific individuals. This means there are no specific regulations in this field of research, so the general statutory provisions apply.

Therefore, for related clinical studies, the general German laws on medicinal products and medical devices apply. They require that participants be provided with full information on any testing and must grant their prior consent. Since genome analysis involves collecting personal data, the General Data Protection Regulation (GDPR) and national data protection regulations also apply. Article 9 of the GDPR classifies genetic data as sensitive data that may only be processed if the data subject has given their explicit consent or with special legal permission. However, the German legislator took advantage of the exemption clauses in Article 89 (2) GDPR. Article 89 states that genetic data may be processed for scientific research purposes even without consent if it would otherwise be impossible to fulfil such purposes and the interests of the party responsible for processing the data significantly outweigh the interests of the data subject in not having data processed. Given the significance of genome sequencing for research, the consent requirement could therefore be dispensed under data protection regulations.

However, this would breach the strict laws on medicinal products and medical devices which require consent to the use of data in clinical studies. Data protection law also entitles data subjects to request information on their data or have their data deleted. This may be difficult to put into practice if large amounts of data have been collected. Another point to be clarified is whether individuals have a right to know or not to know about random genetic findings.

Ultimately, in the absence of specific legislation on genome analysis for research purposes, many legal questions have yet to be answered. It remains to be seen whether the legislator will set out more precise regulations in future.

4. WHERE DO WE GO FROM HERE?

The Federal Ministry of Research (Bundesforschungsministerium) has announced that the next step will be to set up national working groups. A detailed schedule and set of requirements are to be drawn up by mid-2021. Only then will it be possible to develop strategies for the cross-border use of genomic and phenotypic data. According to the Ministry, the first locations for testing the secure sharing of genomic data are to be selected by the end of 2020. On that basis, it will be possible to donate genomes during clinical treatment.

By joining the Genome Initiative, Germany has taken an important step in terms of digital health. Now the task is to adjust the existing legal framework to cover whole genome sequencing and to clarify the remaining legal issues. In future, genome analysis will play a key role not only for major pharmaceutical companies, manufacturers of medical devices, hospitals and research institutes, which are directly or indirectly involved in researching rare diseases, but also for investors. To meet today's legal and regulatory challenges and any further challenges the future may bring, all players will have to keep a close eye on developments in this field.

Follow this link:
Germany Joins the Genomes Initiative - Lexology

Read More...

This Founder Couldn’t Find an Affordable Way to Test Drinking Water After the Flint Crisis, so She Created One – Inc.

Saturday, February 8th, 2020

Editor's note:This article is part of Inc.'s 2020 Best Industries report.

"I love my family, but that's ridiculous," Glover says.

That same year, Glover co-founded120 Water Audit to develop more affordable consumer water testing kits. Now the company also tests and manages drinking water programsfor government agencies, public water systems, schools, and other facilities.120 Water Audit is a leader among a growing group of startups serving utility companies and government agencies that have been forced to update systems and respond togrowing consumer concerns in the wake of crises like Flint.

Turning on the tap

Glover, a former marketing and business development executive, launched 120 Water Audit with co-foundersChris Baggott and Dave Kohl.(Baggott and Kohl were never operational with the company, but Baggott is on the board of directors.) They initially bootstrapped the business and worked out of Glover's parents' garageuntil the company won its first contracts with the city ofPittsburgh, the state of Indiana, andutilities in Loveland, Colorado, and Lewisville, Texas.

To collect samples, the startup sends water bottles that customers fill from the source they wish to test.Each bottle comes with a prepaid return envelope that goes to an EPA-certified lab for testing. Individual water tests rangefrom $54 to $84, depending on the type of analysis. Meanwhile, the company's software helpsclientsaggregate data and automate tasks like sending recurring reports.

120 Water Audit's tests detecttoxins like lead, copper, and arsenic, whichat certain levels have been linked to learning problemsamong children, reproductive issues, and, in rare cases, death, according to the Environmental Protection Agency. Some of these contaminants occur naturally, while othersmake their way into water supplies from manufacturing facilities orinfrastructure failuressuch asold pipes. The Flint water crisis is one of the most recent instances of the latter: The city switched its water source in 2014;officials failed to treat the water and lead from older pipes seeped in.Some residents experienced lead poisoning, while low chlorine levels led to a deadly outbreak of Legionnaire's disease.

The Flint crisis raised consumer awareness of drinking water safety, and as a result,120 Water Audit has seen a steady risein sales since its launch. The company--named for the frequency it believes consumers should test their water, which is every 120 days--booked $3.3 million in revenue last year, up from about $2 million in 2018. Glover declined to share whether the company was profitable.

A flood of activity

Glover's startup isn't the only one to see an increase in activity: Last year, businesses working on clean water initiatives--which tackle a broad array of services, including producing drinkable water from new sources and real-time water monitoring--raised $50.7 million in venture capital funding, according to the data and research company PitchBook. That's a $10.9 million increase from 2014, but it's stilla relatively low amount of VC funding for an entire industry.

120 Water Audit wasone of the best-funded startups in the industry last year: It raised $7 million in venture capital, which makes up 13.8 percent of theindustry's totalventure capital dollars from last year, according to Pitchbook. In total, the company has raised $9.4 million, including a$100,000 first prize from former America Online CEO Steve Case's Rise of the Rest pitch competition. Glovercredits a majority of 120 Water Audit's growth to newly implemented drinking water regulations and stricter water quality specifications in the wake of Flint.

"Consumers are getting a lot more vocal about the quality of their water," she says. "That's forcing [traditional water utility companies] to think differently about the programs they run and how they communicate with consumers."

Crises like Flintare leading consumers to take action by using theseservices or pushing government agencies for more testing,says Reese Tisdale, the president and CEO of Bluefield Research, an independent advisory firm that aims to help companies and organizations address regulatory and business trends in the water sector. "We expect to know what we're ingesting and understand what the impacts are on ourselves and the environment."

Today, 120 Water Audit works with clients in 14 states, including four statewide contracts, and its software has been implemented on more than 175,000 taps, Glover says. The majority of the business is built on partnerships with water systems, while about a fourthgoes to state contracts, says Glover. However, she still receives a steady trickle of individual consumers seeking her water testing kits, but that makes up less than 1 percent of the company's revenue, Glover added.Prices vary depending on the customer's location and size of its water program, but the company's average contract value is just under $270,000 per year.Currently, Glover employs a team of 36 workers.

However, the startup still faces industry-specific challenges, like heavy regulation and a lack of funding from investors."It's not a technology problem, it's that there aren't enough dollars to go around," Tisdale says. "There is no white knight out there with bags of money to save your municipal water supply."

What's more, startups in the clean water space will face stiff competition from larger companies that offer diversified services and have the financials to withstand market changes or slow adoption rates, Tisdale says. Prominent U.S.-based heavyweightsinclude Xylem and Danaher, both of which are public companies that own multiple brands in the clean water space, he adds.

Glover is lookingto expand 120 Water Audit's reach by launching a commercial application later this year. The program would give safe drinking water certifications to establishments like hotels and restaurants.

As for the results of the water analysis in her own home, Glover was relieved to learn her tap water was safe. She says she wants to give many more people the same peace of mind. "Once you know a lot of this stuff, you can't unknow it."

Published on: Feb 4, 2020

Read more here:
This Founder Couldn't Find an Affordable Way to Test Drinking Water After the Flint Crisis, so She Created One - Inc.

Read More...

An Ex-NASA Employee Is Launching Satellites Into Space to Predict the Future and Help Save Lives – Inc.

Saturday, February 8th, 2020

When Malaysia Airlines Flight 370 disappeared on its way from Kuala Lumpurto Beijingin 2014, aerospace engineer Payam Banazadeh, then 23, fixated on one question: Why couldn't satellites scan the area where the plane disappeared in real-time?

"As I pulled the thread, what was very clear was that there was a huge gap in monitoring our planet from space," Banazadehsays.

Of thehundreds of schoolbus-size Earth-observation satellites currently in orbit, the majority use optical imaging, which typically can't see 75 percent of the Earth's surface because of weather issues and darkness, according to Banazadeh. At the same time, the cost of sending satellites into orbit is falling dramatically as governments and private companies launch a growing number of rockets into space, creating new opportunities for entrepreneurs to puteyes in the sky.

Banazadeh, a former project manager at NASA, saw a problem he could solve and the perfect moment to do it, so he founded Capella Space in 2016 with the goal of developing a smaller, more powerful satellite. In 2019, the company launched its first prototype satellite Denali, a backpack-size device that uses a technology called Synthetic Aperture Radar (SAR), which can see through clouds and at night.

In 2020, Capella will launch sevensatellites that togetherwill be able to monitor the entire surfaceofthe planeteverysix hours, on average, according to Banazadeh. The company will launch an additional sixto 12 satellites per year until it has 36 in orbit, at which point he says the time between updates will drop from up six hours to up to one hour. Capella will allow customers to submit requests for data and imagery through an automated system in a matter of minutes,16 times faster than rivalcompanies can, according to Banazadeh.

A wide range of applications

Unlike optical imaging satellites, which relyon incominglight to produce an image, Capella's satellites send a radar signalthat hits the Earth's surface and is reflected back to the satellite.The resulting data is used to produce an image that can detect changes tothe Earth's surfaceless than a meter in size. The structural integrity of a bridge, for example, can be monitored over time to determine whether maintenance workneeds to be done.

Although Capella's fleet of satellites isn't commercially operational yet,the companyhas already signed multimillion-dollar contracts with U.S. government agencies, including the U.S. Air Force and the Department of Defense's National Reconnaissance Office. "We will be monitoring certain spots for them and alerting them of any change," Banazadeh says.

The applications for Capella's servicesextendfar beyond providing information for governmentagencies.Banazadehsaysthe companyhas deals in place with private sector customers, thoughhe can't disclose their names.Being able to trackthe supply chain ofmajorcommodities like oil is onecapability hesays will create significant value.And because Capella's radar can also measurethe moisture levels of soil, monitoringthe health of crops for the agricultural industry represents another opportunity. Perhaps the most valuable service will beprovidinginformation tofirst responders during emergencies like storms, fires, andother natural disasters.

"The ability for us to immediately look through the clouds while the storm or disaster is happening, do damage assessment, and provide thatto the first responders to tell them what the best route is--those are the types of interactions we can start having," Banazadeh says.

Lower costs mean greater opportunity

With around 100 rocket launches taking place every year,the cost of sending satellitesinto space has fallen to between $20,000 and $40,000per kilogram. "It used to be that governments would launch these gigantic, billion-dollar satellites into space once every couple years," says Todd Dagres, a co-founder at Spark Capital, one of Capella's investors. "What's happened is, the bar has dropped so precipitously that countries that before could hardly get a train to run on time are pumping iron to the sky."

Elon Musk's SpaceXrecently began offering monthly missions to small satellite operators starting at $1 million, or$5,000 per kilogramfor up to 200 kilograms of payload mass.(In March, Capella's first operational satellite, called Sequoia, is scheduled tolaunch on a SpaceX Falcon 9 rocket from Cape Canaveral, Florida.) Theindustry also has benefited from lower costs for the components required to build small satellites. "A lot of that is driven by the commercial electronics industry--the stuff that is feeding the newest features on our iPhones and laptops,"says Mike Safyan, vice president of launch at Planet, an Earth-observation company that provides satellite imagery data. "That's being folded into the space industry in a way that hasn't really been done before."Capella declined to disclose how much it costs to buildits satellites.

Venture capital investment into space technology companies hasgrown to $2.27 billion in 2019 from $2.6 million in 2011, according to market data provider PitchBook.Capella has raised more than $80 million in funding, primarily from venture capital firms Data Collective andSpark Capital. The global nanosatellite and microsatellite marketis expected to grow to $3.6 billion by 2024 from $1.5 billion in 2019, according to research firm MarketsandMarkets.

Companies that provide satellite observation services similar to Capella's, albeit using much larger satellites, include multinational aerospace corporation Airbus and Italian company e-GEOS.Banazadeh says the value Capella brings is significantlydifferent from what these companies can offer thanks to its constellation that can repeatedly observe specific areas of the planet.

"They have these giant satellites that can do more things thanour satellites can do, but they can't really have the cadence at the cost that we can provide," he says. "I think we're very much complementary with those guys."One startup competitor isJapaneseSAR company Synspective, which raised $100 million in funding last July. Twoof the biggest challenges facing all satellite companies, according to Banazadeh,aresecuring reliable launch vehicles andputting satellites into orbit on time, asrockets are in high demand and launch delays are the norm rather than the exception.

In as soon as the next five years, Banazadehsays Capella's data could be useful for predicting future events, like where illegal fishingis likely to take place.

"If I were looking at that area from space using my satellite and combining it with other satellites and other data--this is the route they take and this is what the boat looks like--the next time I can start predicting who is doing what," he says. "As we start building this really dense data set of high quality and high cadence, that's going to be really interesting."

Published on: Feb 4, 2020

See the original post here:
An Ex-NASA Employee Is Launching Satellites Into Space to Predict the Future and Help Save Lives - Inc.

Read More...

Page 5«..4567..10..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick